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Targeting a specific chemokine/receptor axis in atherosclerosis remains challenging. Soluble
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continuous architecture. Macrophage migration-inhibitory factor (MIF) is an atypical che-
mokine that promotes atherosclerosis through CXC-motif chemokine receptor-4 (CXCR4).
However, CXCR4/CXCL12 interactions also mediate atheroprotection. Here, we show that
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entiates between disease-exacerbating and -protective pathways and chemokine-selectively
interferes with atherosclerosis.
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hemokines are chemotactic cytokines that orchestrate cell
trafficking and behavior in homeostasis and disease. Four
chemokine sub-classes and their G protein-coupled
receptor (GPCR)-type receptors (CKRs) constitute a complex
ligand/receptor-network characterized by both specificity and
redundancy1,2. Chemokines are pivotal players in various
inflammatory diseases, including atherosclerosis1,3. Therapeutic
anti-cytokine approaches are successfully used in several
inflammatory diseases and the positive results obtained with an
interleukin-1β (IL-1β)-blocking antibody in the CANTOS trial
have validated the inflammatory paradigm of atherosclerosis in
humans and demonstrated the potential utility of anti-
inflammatory drugs in patients with atherosclerotic disease.
However, CANTOS also highlighted the need for molecular
strategies with improved selectivity and less side effects4.
While anti-chemokine strategies such as antibodies or small
molecule drugs (SMDs) have been established, targeting a specific
chemokine/receptor axis remains challenging due to the pro-
miscuity in the chemokine network1,3,5,6. In addition to anti-
bodies and SMDs, soluble receptor-based approaches have proven
as a powerful anti-cytokine strategy in inflammatory/immune
diseases. For example, soluble tumor necrosis factor-receptor-1
(TNFR1)-based drugs are in clinical use for rheumatoid arthritis7.
However, soluble receptor-based approaches are not established
for chemokine receptors because of the discontinuous nature of
the GPCR ectodomain topology.
Macrophage migration-inhibitory factor (MIF) is an evolutio-
narily conserved, multi-functional inflammatory mediator that is
structurally distinct from other cytokines8–12. The MIF protein
family also comprises D-dopachrome tautomerase (D-DT)/MIF-
213. MIF is an upstream regulator of the host innate and adaptive
immune response, and, if dysregulated, is a key driver of acute and
chronic inflammation, and cardiovascular diseases including
atherosclerosis8,9,11,12,14–18. Atherosclerotic vascular inflammation
from leukocyte recruitment to foam cell formation and advanced
plaque remodeling is orchestrated by chemokines1,3. Examples are
the classical chemokines CC-motif chemokine ligand 2 (CCL2)
and CXC-motif chemokine ligand 1 (CXCL1)/CXCL8, but atypi-
cal chemokines (ACKs) that are structurally different from clas-
sical chemokines and yet interact with CKRs, have emerged as
additional players in inflammation and atherogenesis16,17. Con-
trary to its eponymous name, MIF is recognized as a prominent
ACK that enhances atherogenic leukocyte recruitment through
non-cognate interactions with CXC-motif chemokine receptors
type 2 (CXCR2) and 4 (CXCR4)14,16,17. Furthermore, MIF (and
also MIF-2) are the sole ligands for the single-spanning type-II
membrane protein CD74/invariant chain, through which they
exert cardioprotective effects in the ischemic heart15,16,19,20.
We recently elucidated the structural determinants of the
binding interface between MIF and its receptors. Binding of MIF
to CD74 involves MIF residues Pro-2, 80–87, and Tyr-100, while
MIF binding to CXCR2 requires a pseudo-ELR motif, similar to
CXCL819,21–23. In contrast, the cognate CXCR4 ligand CXCL12/
stromal cell-derived factor-1alpha (SDF-1α) is an ELR-negative
chemokine and the CXCL12/CXCR4 interface involves the
receptor N-terminus and the RFFESH motif of CXCL12 at site 1
and the chemokine N-terminus and an intramembrane receptor
groove at site 2. MIF binding to CXCR4 encompasses an exten-
ded N-like loop of MIF with contribution from Pro-2. Unlike for
CXCL12, the MIF N-terminus around Pro-2 is rigid and likely
unable to insert into the groove of CXCR4. On the side of
CXCR4, segments of extracellular loop 1 (ECL1) and extracellular
loop 2 (ECL2) but not extracellular loop 3 (ECL3) contribute to
the MIF/CXCR4 interface24,25.
We thus reasoned that designing CXCR4 ectodomain-derived
peptides mimicking its interaction surface with MIF might be a
promising approach to develop receptor-selective MIF inhibitors.
Moreover, as the CXCL12/CXCR4 pathway exhibits critical
homeostatic functions in resident arterial endothelial and smooth
muscle cells and has a critical atheroprotective role26,27, we aimed
to generate CXCR4 mimics specific for MIF/CXCR4, while
sparing CXCL12 pathways. Such mimics would be soluble che-
mokine receptor ectodomain-based inhibitors with receptor- and
agonist-selective targeting properties. This approach would
address current gaps in tailored chemokine-selective targeting
strategies and receptor-specific MIF therapeutics in inflammatory
and cardiovascular diseases.
Using rational peptide design, structure-activity relationships
(SAR), and an array of biophysical methods, we here report on
engineered CXCR4 ectodomain-derived peptide mimics that
selectively bind to the atypical chemokine MIF but not to
CXCL12. Signaling experiments, chemotaxis, foam cell formation,
and leukocyte recruitment studies in vitro and in the athero-
sclerotic vasculature demonstrate that such mimics can act as
agonist-specific anti-atherogenic compounds, blocking CXCR4-
mediated atherogenic MIF activities, while sparing CXCL12 and
protective MIF/CD74-dependent signaling in cardiomyocytes.
We show that the CXCR4 mimic msR4M-L1 is not only enriched
in atherosclerotic plaque tissue in a MIF-specific manner in
mouse and human lesions, but functionally protects from lesion
development and atherosclerotic inflammation in an atherogenic
Apolipoprotein e-deficient (Apoe–/–) model in vivo.
Results
Designing chemokine-selective CXCR4 ectodomain mimics.
Our previous peptide array and SAR studies showed that residues
97–110 of ECL1 and 182–196 of ECL2 of the CXCR4 ectodomain
contribute to the interface between MIF and CXCR425. We rea-
soned that this could be a basis to engineer soluble MIF-binding
CXCR4 mimics. Peptides ECL1[97–110] and ECL2[182–196]
were synthesized by solid-phase peptide synthesis (SPPS) using
Fmoc chemistry28. A synthetic linker was chosen based on the
CXCR4 X-ray structures28–30. We designed and generated the
conformationally constrained ectodomain mimic CXCR4-ECL1
[97–110]-6-Ahx-12-Ado-ECL2[182–196] (MIF-specific human
CXCR4 mimic-ECL1[97–110]-6-Ahx-12-Ado-ECL2[182–196] or
‘msR4M-L1’; Fig. 1a, b; Supplementary Fig. 1; Supplementary
Table 1; Supplementary Fig. 2) that contained a 6-aminohexanoic
acid (6-Ahx)/12-amino-dodecanoic acid (12-Ado) linker with a
spacer length of 2.358 nm. 8-amino-3,6-dioxaoctanoic acid
(O2Oc)/12-Ado was chosen as an alternative, more hydrophilic,
linker (‘msR4M-L2’; Supplementary Fig. 1; Supplementary
Table 1; Supplementary Fig. 3). We also synthesized the non-
linked loop peptides for comparison as well as variants of
msR4M-L1 and -L2 that were additionally constrained by a dis-
ulfide bridge in the presence (msR4M-L1ox and -L2ox) or
absence of the synthetic linker (msR4M-LS) (Supplementary
Table 1). We did not include residues of the CXCR4 N-terminal,
because this region has been implicated as a critical region con-
tributing to the CXCL12/CXCR4 interface29–31, which we wished
to specifically exclude from our targeting strategy.
To determine whether the CXCR4 ectodomain mimics bind to
MIF, we first applied fluorescence titration spectroscopy32,33,
measuring changes in fluorescence emission of Fluos-labeled
ectodomain peptide upon titration against MIF or CXCL12.
Conversely, Alexa-Fluor 488-labeled MIF (Alexa-MIF) was
titrated against unlabeled ectodomain peptides. As determined
by this method, msR4M-L1 exhibited high-affinity binding to
MIF with an apparent (app.) KD ≤ 40 nM (app. KD Fluos-
msR4M-L1/MIF= 40.7 ± 4.0 nM; app. KD msR4M-L1/Alexa-
MIF= 31.1 ± 16.6 nM), whereas no binding to CXCL12 was
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observed (app. KD > 6 µM) (Table 1; Fig. 1c, d; Supplementary
Fig. 4). msR4M-L2 bound to MIF with similar affinity and also
lacked CXCL12 binding (app. KD Fluos-msR4M-L2/MIF= 18.6
± 2.9 nM; app. KD msR4M-L2/Alexa-MIF= 40.5 ± 7.6 nM; app.
KD Fluos-msR4M-L2/CXCL12 > 6 µM; Table 1; Supplementary
Fig. 4). Thus, both mimics exhibited a > 140-fold selectivity for
MIF versus CXCL12. Interestingly, fluorescence titration spectro-
scopy measurements also indicated that additional conforma-
tional restriction of the mimics by disulfide bridging leads to an
induction of CXCL12 binding, while high-affinity MIF binding
was preserved in such analogs (Table 1; Supplementary Fig. 4). By
contrast, the single, non-linked ECL peptides ECL1[97–110] and
ECL2[182–196] only exhibited a medium-low binding affinity for
MIF (app. KD ECL1/Alexa-MIF= 345.2 ± 79.4 nM; app. KD
ECL2/Alexa-MIF= 2458 ± 1054 nM; Table 1; Supplementary
Fig. 4).
Of note, circular dichroism (CD) spectroscopy indicated
that especially msR4M-L1 is well-structured (Fig. 1e). CD
spectroscopy also confirmed our design strategy with appreciable
conformational restriction introduced by the 6-Ahx-12-Ado
linker of msR4M-L1, as a non-linked mixture of ECL1 and 2
exhibited mostly random coil conformation (Supplementary
Fig. 5). Thus, the initial fluorescence and CD spectroscopic
experiments suggested that msR4M-L1 (and -L2), but not the
disulfide-bridged or single ECL loop variants, could represent
promising CXCR4 mimics with high selectivity for MIF versus
CXCL12. However, fluorescence spectroscopy also indicated that
both msR4M-L1 and -L2 exhibit some degree of self-assembly
propensity (app. KD Fluos-msR4M-L2/msR4M-L2= 69.6 ± 61.9
nM versus Fluos-msR4M-L1/msR4M-L1= 142.0 ± 48.9 nM; Sup-
plementary Fig. 6). Although this was 2-fold lower for msR4M-L1
compared to -L2 and the concentrations of msR4M-L1 used in
the fluorescence spectroscopic titrations were >25-fold lower than
the app. KD of its self-assembly, we sought to support our findings
by additional methods, as fluorescence intensity may be affected
by several factors. First, we applied fluorescence polarization (FP),
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Fig. 1 The CXCR4 ectodomain mimic msR4M-L1 selectively binds to MIF but not CXCL12. a Schematic summarizing the design strategy to utilize
extracellular loop moieties of CXCR4 to engineer a soluble mimic that binds MIF but not CXCL12. b Ribbon structure of human CXCR4 based on the crystal
structure according to PDB code 4RWS30. Sequences of extracellular loops ECL1 and ECL2 that were found to interact with MIF according to peptide array
mapping25 are highlighted in blue, and the N- and C-terminal residues of the ECL1 and 2 peptides are indicated. c Nanomolar affinity binding of msR4M-L1
to MIF as determined by fluorescence spectroscopic titrations. Emission spectra of Fluos-msR4M-L1 alone (blue; 5 nM) and with increasing concentrations
of MIF at indicated ratios are shown (left panel; representative titration); binding curve derived from the fluorescence emission at 522 nm (right panel).
dmsR4M-L1 does not bind to CXCL12. Same as c but titration performed with increasing concentrations of CXCL12. e Conformation of CXCR4 ectodomain
mimics as determined by far-UV CD spectroscopy. Mean residue ellipticity plotted over the wavelength between 195 and 250 nm. f–g Nanomolar binding
of msR4M-L1 to MIF (f) but not CXCL12 (g) as determined by fluorescence polarization (FP). The FP signal of 5 nM Fluos-msR4M-L1 (as mP) is plotted
over varied ligand concentration as indicated. h, i Binding of msR4M-L1 to MIF (h) but not CXCL12 (i) as confirmed by microscale thermophoresis (MST).
The fraction of chemokine bound or normalized fluorescence change (ΔFnorm) to 100 nM TAMRA-msR4M-L1 is plotted against increasing concentrations
of MIF or CXCL12, respectively. j Binding analysis between TAMRA-msR4M-L1 and MIF versus CXCL12 as determined by dot blot titration. Quantification
from three independent blots (see representative blot in Supplementary Fig. 8). Data in c–d (right panel) and f–h are reported as means ± SD from three
independent experiments; data in i are means ± SD from five independent experiments. Statistical analysis (j) was performed with two-way ANOVA and
Sidak correction. CXCR4, CXC motif chemokine receptor-4; msR4M-L1, MIF-specific CXCR4 mimic-L1; MIF, macrophage migration-inhibitory factor.
Source data are provided as a Source Data file.
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which is a robust method for quantifying affinities of protein-
protein interactions and has previously been applied to study MIF
interactions34. Confirming the results obtained by fluorescence
spectroscopy, incubation of Fluos-msR4M-L1 with increasing
concentrations of MIF resulted in significant changes in FP and
an app. KD in the low nanomolar range was determined (app.
Fluos-msR4M-L1/MIF= 24.4 ± 5.3 nM; Fig. 1f). A similar app.
KD was obtained for the Alexa-MIF/msR4M-L1 interaction (app.
KD Alexa-MIF/msR4M-L1= 10.6 ± 1.2 nM; Supplementary
Fig. 7). In contrast, no change in FP was observed, when Fluos-
msR4M-L1 was titrated with CXCL12 (app. KD > 2.5 µM; Fig. 1g).
In addition to FP, the interactions between msR4M-L1 and MIF
or CXCL12 were studied by microscale thermophoresis (MST).
For the interaction between 5(6)-carboxytetramethylrhodamine
(TAMRA)-msR4M-L1 and MIF an app. KD of 77.2 ± 37.1 nM
was found (Fig. 1h). By contrast, the app. KD of the TAMRA-
msR4M-L1/CXCL12 interaction was >3 µM (Fig. 1i). Thus, the
FP and MST studies confirmed the findings of the fluorescence
spectroscopic titrations (summarized in Table 1). Further
evidence for the selectivity of the interaction between msR4M-
L1 and MIF as compared with CXCL12 was obtained by a dot
blot experiment, in which immobilized MIF and CXCL12 were
probed on a dot blot membrane with TAMRA-msR4M-L1. MIF
was readily detected in a concentration-dependent manner,
whereas TAMRA-msR4M-L1 showed no binding to CXCL12
(Fig. 1j; Supplementary Fig. 8).
MIF residues 80–87 and Tyr-100 are specific determinants of
the interaction between MIF and CD74, whereas Pro-2 of MIF
contributes to both MIF/CD74 binding and the MIF/CXCR4
interface21,22,25. We therefore also applied FP and MST in a
binding-competition approach to experimentally confirm that
msR4M-L1 does not interfere with MIF binding to its receptor
CD74, which mediates MIF’s cardioprotective activity15. Apply-
ing FP, we determined an app. KD of 114.4 ± 47.0 nM for the
interaction between Alexa-MIF and an HA-tagged soluble
ectodomain of CD74 (HA-tagged sCD74(73–232)), overall in
line with the previously measured binding affinity between MIF
and CD7419. Binding was not affected by co-incubation of MIF
with msR4M-L1 (app. KD= 89.4 ± 55.3 nM; P= ns) (Supple-
mentary Fig. 9). MST experiments confirmed that binding
between MIF and CD74 was not inhibited by msR4M-L1.
Titration of Alexa-647-labeled MIF with increasing concentra-
tions of HA-tagged sCD74(73–232) was not influenced by
msR4M-L1 (app. KD Alexa-647-MIF/HA-sCD74(73–232) =
33.9 ± 5.0 nM; Alexa-647-MIF/HA-sCD74(73–232) + msR4M-
L1= 34.5 ± 13.1 nM; P= ns; Supplementary Fig. 9).
Together, the data demonstrate that msR4M-L1, an engineered
soluble CXCR4 ectodomain mimic, binds with high affinity to
MIF, exhibiting binding selectivity for MIF versus the cognate
ligand CXCL12, while not interfering with MIF/CD74 binding.
This led us to prioritize msR4M-L1 for further analysis.
Mapping and mutation of the MIF/msR4M-L1 binding region.
We mapped the binding region in MIF and msR4M-L1 by
fragment approach and alanine-scanning (Fig. 2a, b). As our
structure-activity studies on the MIF/CXCR4 interface had pro-
vided evidence for a role of the N-like loop24,25, we started the
mapping with a MIF peptide fragment spanning this region
(Fig. 2a). Applying fluorescence spectroscopy, MIF peptide 38–80
was found to bind to msR4M-L1 with similar affinity as full-
length MIF (app. KD Fluos-msR4M-L1/MIF[38–80] = 57.1 ± 7.8
nM; Fig. 2a,c; Supplementary Table 2; Supplementary Fig. 10). As
the peptide lacks the 3D conformation of folded full-length MIF,
this suggested that a locally-defined sequence was important for
the interaction with the ectodomain mimic. Moreover, detailed
mapping of the msR4M-L1/MIF binding region by analyzing
various 14–30-meric MIF peptide fragments spanning regions
within and outside of sequence 38–80, narrowed the core binding
region in MIF to sequence 50–80 or 54–80 (app. KD Fluos-
msR4M-L1/MIF[50–80] = 55.2 ± 9.9 nM; app. KD Fluos-msR4M-
L1/MIF[54–80] = 70.6 ± 14.2 nM; Fig. 2d; Supplementary
Table 2; Supplementary Fig. 10). On the other hand, peptide
segment 6–23, which is outside the core region, or 62–80 which is
situated at the far C-terminal end of the core, did not bind to MIF
(app. KD Fluos-msR4M-L1/MIF[6–23] >20 µM; app. KD Fluos-
msR4M-L1/MIF[62–80] >10 µM; Fig. 2e; Supplementary Table 2;
Supplementary Fig. 10; Supplementary Fig. 11). Notably, the
identified MIF core region bound to msR4M-L2 as well (app. KD
Fluos-msR4M-L2/MIF[50–80] = 30.9 ± 20.4 nM; app. KD Fluos-
msR4M-L2/MIF[54–80] = 52.9 ± 25.6 nM).
To further map the inhibitor binding region of MIF as well as
the binding determinants of msR4M-L1 and verify the specificity
of msR4M-L1/MIF complex formation, we next studied alanine
mutants of both msR4M-L1 and MIF. Synthetic peptide arrays
comprising 14–15-meric segments within msR4M-L1-related
ECL1 and ECL2 sequences in combination with extensive
alanine-scanning and array probing with biotinylated human
MIF (Supplementary Table 1; Supplementary Fig. 12) guided us
regarding the critical residues within msR4M-L1. Using single,
double, and triple alanine mutants, sequences 102–108 and
188–196 containing several aromatic residues were identified as
possible MIF binding core regions in the ECL1 and ECL2 parts of
msR4M-L1, respectively. Accordingly, the aromatic Phe, Trp, and
Tyr residues in position 102, 103, 104, 107, 189, 190, and 195
could be key determinants of msR4M-L1 binding to MIF
(Supplementary Fig. 12). We applied fluorescence titration
spectroscopy to study the MIF binding properties of a mutant
of msR4M-L1, in which all of these aromatic residues were
substituted by Ala, i.e. analog [A102, A103, A104, A107, A189, A190,
A195]-msR4M-L1 or msR4M-L1(7xAla). In fact, disruption of the
predicted core MIF binding site in msR4M-L1(7xAla) ablated its
Table 1 Binding affinities between the CXCR4 ectodomain
peptides and MIF versus CXCL12 as determined by
fluorescence titration spectroscopy, fluorescence

















msR4M-L1 40.7 ± 4.0 31.1 ± 16.6 >6340
msR4M-L2 18.6 ± 2.9 40.5 ± 7.6 >6340
msR4M-L1ox 28.9 ± 2.5 30.0 ± 6.3 84.6 ± 42.1
msR4M-L2ox 105.3 ± 44.9 59.6 ± 15.3 54.8 ± 10.3
msR4M-LS 6.9 ± 2.0 n.d. 17.4 ± 4.7
ECL1 n.d. 345.2 ± 79.4 n.d.
ECL2 >5000 2458 ± 1054 n.d.
Fluorescence polarization (FP)
msR4M-L1 24.4 ± 5.3 10.6 ± 1.2 >2500
Microscale thermophoresis (MST)
msR4M-L1 77.2 ± 37.1 n.d. >3125
aFor fluorescence spectroscopy and FP, Fluos-labeled ECD peptides were used at a
concentration of 5 nM
b For MST, TAMRA-labeled ECD peptide was used at a concentration of 100 nM
c Reported apparent KD values are means ± SD from 3 (fluorescence spectroscopy and FP) or 5
(MST) independent experiments and were calculated as described in Methods
d Alexa-MIF was used at a concentration of 10 nM
eAlexa-CXCL12 measurements were not pursued, because of the notion that Alexa labeling
could interfere with the crucial residue Lys-1 of CXCL1230 as well as other binding-relevant
lysines. ECD, extracellular domain; app., apparent; n.d., not determined
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binding to MIF (Fig. 2f; app. KD Fluos-msR4M-L1(7xAla)/MIF >
1 µM). As alanine substitutions of Phe-104 and Phe-107 caused
the strongest observed reductions in spot intensity, we also
determined whether the substitution of only these two residues
would affect the binding capacity of msR4M-L1. In fact, peptide
[A104, A107]-msR4M-L1 or msR4M-L1(2xAla) displayed sub-
stantially reduced binding to MIF (Supplementary Fig. 13; app.
KD Fluos-msR4M-L1(2xAla)/MIF > 1 µM). In line with the
binding data, CD spectroscopy showed that msR4M-L1(7xAla)
and msR4M-L1(2xAla) fully and partially, respectively, lost the
well-defined structure of msR4M-L1 and their spectra were
consistent with large portions of random coil structure (Supple-
mentary Fig. 13). We also performed an inverse mutation
experiment, in which residues 47–56 within the MIF binding core
were substituted by alanine by PCR mutagenesis. Mutant
[A47–56]-MIF or MIF(10xAla) only retained a minimal binding
activity to msR4M-L1 as determined by fluorescence titration of
Fluos-msR4M-L1 and this mutant (Fig. 2g; app. KD Fluos-
msR4M-L1/MIF(10xAla) >500 nM). Lastly, we performed a dot
blot-based competition experiment, in which the capacity of
peptide MIF[54–80] (representing the core binding region of
MIF) to compete with the binding between MIF and TAMRA-
msR4M-L1 was tested. When TAMRA-msR4M-L1 was co-
incubated with MIF[54–80], binding to immobilized MIF was
markedly reduced (Fig. 2h).
Together, these data further confirmed the specificity of msR4M-
L1/MIF complex formation. They also indicate that the
aromatic residues in msR4M-L1, in particular Phe-104 and Phe-
107, play a critical role for the binding to MIF and that the msR4M
binding determinants of MIF are mainly located in MIF sequence
stretch 38–80, or even 54–80, consistent with a role of the N-like
loop25.
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Fig. 2 Mapping of the MIF/msR4M-L1 core binding region and complex disruption by mutations. a Amino acid sequence of human MIF (boxed, top).
The msR4M-L1 binding core region of MIF (sequence 38–80 and 54–80) is indicated in blue, while non-binding stretches are in gray (bottom). b Sequence
of msR4M-L1. Aromatic residues identified by peptide array to be critical for MIF binding are highlighted in red. c–e Nanomolar affinity binding of msR4M-
L1 to MIF(38–80) (c) and MIF(54–80) (d), but not MIF(6–23) (e), as determined by fluorescence spectroscopy. Emission spectra of Fluos-msR4M-L1
alone (blue; 5 nM) and with increasing concentrations of MIF(38–80) (c), MIF(54–80) (d), and MIF(6–23) (e) (left panels; representative titrations);
binding curves derived from the fluorescence emission at 522 nm (right panels). f–g Binding of msR4M-L1 to MIF is blunted when aromatic residues in
msR4M-L1 are substituted by Ala in analog msR4M-L1(7xAla) (f) or when N-loop residues in MIF are mutated to Ala in MIF(10xAla) (g). Fluorescence
spectroscopy and binding curve as in c–e. Data in right panels of c–g are means ± SD from three independent experiments. h Dot blot shows that binding of
TAMRA-msR4M-L1 to spotted MIF is attenuated by MIF(54–80). 400 ng spotted MIF was probed with TAMRA-msR4M-L1 +/− 2-fold molar excess of
MIF(54–80); RFU, relative fluorescent units. The blot shown is one of three dot blots performed. msR4M-L1, MIF-specific CXCR4 mimic-L1; MIF,
macrophage migration-inhibitory factor. Source data are provided as a Source Data file.
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Ectodomain mimics selectively block MIF/CXCR4 activity. To
scrutinize whether selective msR4M-L1/MIF binding correlates
with inhibition of MIF-triggered inflammatory and atherogenic
effects, we first examined whether msR4M-L1 interfered with
MIF/CXCR4-specific cell signaling. We took advantage of a yeast
strain that expresses human CXCR4 and specifically measures
agonist-mediated activation of CXCR4 via a reporter plasmid25.
Confirming previous data25, MIF triggered CXCR4-mediated
signaling, but co-incubation of MIF with msR4M-L1 blocked the
β-galactosidase reporter signal in a concentration-dependent
manner (Fig. 3a). In contrast, CXCL12/CXCR4-elicited signaling
remained unaffected by msR4M-L1 (Fig. 3b). This suggested that
msR4M-L1 specifically blocks MIF/CXCR4-driven cell signaling
responses.
Receptor signaling analysis in our yeast system is limited to
GPCRs and not amenable to the non-GPCR receptor CD74. The
FP and MST experiments with sCD74 indicated that msR4M-L1
does not affect MIF/sCD74 binding (Supplementary Fig. 9), but
to verify that msR4M-L1 also does not interfere with the MIF/
CD74 axis in a cell-based system, we transfected HEK293 cells
with a construct driving CD74 surface expression14. Alexa-MIF
cell-surface binding as measured by flow cytometry was elevated
in a CD74-dependent manner. Of note, co-incubation of Alexa-
MIF with a 5-fold molar excess of msR4M-L1 did not reduce
surface binding of Alexa-MIF (Fig. 3c). Together, the yeast-
CXCR4 and HEK293-CD74 transfectant data showed that
msR4M-L1 blocks the interaction between MIF and cell-
surface-expressed CXCR4, whereas binding to cell-surface
CD74 is not affected.
We next asked whether msR4M-L1 also selectively inhibits
MIF responses in mammalian cell systems expressing endogenous
CXCR4. B lymphocytes express substantial levels of CXCR4 and
MIF has been shown to trigger murine B-cell chemotaxis in a
CXCR4-dependent manner35. Human and murine MIF share
90% amino acid identity and there is a high degree of cross-
species receptor activity36. There also is a high degree of sequence
identity between human and murine MIF in the binding region
for msR4M-L1 (MIF(38–80): 86%; MIF(54–80): 89%), and by
applying dot blot titration, we confirmed that msR4M-L1 binds
equally well to human and mouse MIF (Supplementary Fig. 14).
We then subjected primary splenic B cells to MIF-triggered
chemotaxis using the Transwell system. When co-incubated with
MIF, msR4M-L1 (as well as msR4M-L2; Supplementary Fig. 15)
fully blocked MIF-mediated B-cell chemotaxis in a concentration-
dependent manner with maximal inhibition seen at a 5-fold
molar excess (Fig. 3e) and an IC50 in the range of 10–15 nM
(Supplementary Fig. 15). In contrast, msR4M-L1 was unable to
inhibit chemotaxis elicited by CXCL12 (Fig. 3f). Of note, analog
msR4M-L1(7xAla) with seven binding-determining residues
substituted by Ala failed to inhibit MIF-elicited chemotaxis
(Fig. 3f), while analog msR4M-L1(2xAla) with only two Ala
substitutions retained partial chemotaxis-inhibitory activity
(Supplementary Fig. 16), confirming the specificity of binding
inhibition in a relevant cell-based assay. Thus, the yeast signaling
and B-cell migration data suggested that msR4M-L1 potently and
selectively interferes with MIF/CXCR4-mediated cell responses.
MIF is a pro-atherogenic cytokine, but also has context-















































































































































































































































Fig. 3 msR4M-L1 selectively inhibits MIF-triggered CXCR4 activity, but spares the MIF/CD74 axis. a, b MIF (a) but not CXCL12 (b) binding to and
signaling through human CXCR4 in an S. cerevisiae system is attenuated by msR4M-L1 in a concentration-dependent manner. The molar excess of
competing msR4M-L1 over MIF or CXCL12 is indicated. CXCR4 binding/signaling is read out by LacZ reporter-driven luminescence. c A 5-fold molar
excess of msR4M-L1 does not interfere with binding of Alexa 488-MIF to CD74 expressed on HEK293-CD74 transfectants as measured by flow
cytometry. Left, shift of CD74 transfectants following Alexa 488-MIF binding (control indicates background); right, quantification of three independent
experiments. d, e Chemotactic migration (Transwell) of primary mouse spleen B lymphocytes elicited by 16 nM MIF (d) or CXCL12 (e) as chemoattractant
and inhibitory effect of msR4M-L1. msR4M-L1 dose-dependently inhibits MIF-mediated chemotaxis (d), but the optimal inhibitory dose of 80 nM does not
affect CXCL12-elicited chemotaxis (e). fmsR4M-L1 analog msR4M-L1(7xAla) does not inhibit MIF-mediated chemotaxis. msR4M-L1(7xAla) was applied at
a concentration of 80 nM. g msR4M-L1 does not interfere with MIF-triggered AMPK signaling in the human cardiomyocyte cell line HCM. MIF was applied
at a concentration of 16 nM; msR4M-L1 added at 1- and 5-fold excess over MIF. AMPK signaling was measured using Western blot of HCM lysates
developed against pAMPK and total AMPK. The densitometric ratio of pAMPK/AMPK indicates signaling intensity. Data are reported as means ± SD of
n= 3 (a); n= 4 (b); n= 3 (c, right panel); n= 6 (d); n= 3 (e–f); and n= 5 (g) independent biological experiments. Statistical analysis was performed with
unpaired two-tailed T-test. CXCR4, CXC motif chemokine receptor-4; msR4M-L1, MIF-specific CXCR4 mimic-L1; MIF, macrophage migration-inhibitory
factor. Source data are provided as a Source Data file.
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Before further evaluating the translational potential of our
findings, we wished to exclude that msR4M-L1 interferes with
protective MIF/CD74-mediated signaling in cardiomyocytes.
Primary human cardiomyocytes (HCM; expressing CD74,
Supplementary Fig. 17) were incubated with MIF in the presence
or absence of msR4M-L1. We then analyzed phosphorylated
AMP kinase (pAMPK) levels, a correlate of protective MIF/
CD74-mediated signaling. As demonstrated previously15, MIF
upregulated pAMKP levels, but this effect was not attenuated by
msR4M-L1 (Fig. 3g; Supplementary Fig. 17), confirming that the
CXCR4 mimic does not cross-affect MIF activities through CD74.
msR4M-L1 blocks atherogenic MIF activity in vitro/ex vivo.
MIF is a driver of atherogenic monocyte activity and inhibition of
monocyte-dependent atherogenic inflammation is a preferred
strategy to limit atherosclerotic lesion formation. As both MIF
and CXCR4 have previously been linked to macrophage foam cell
formation37,38, we tested the effect of msR4M-L1 on MIF-
triggered uptake of fluorescently labeled oxidized low-density
lipoprotein (DiI-oxLDL) by human macrophages derived from
peripheral blood mononuclear cells (PBMCs). MIF doubled foam
cell formation in this setting and this effect was blocked by the
pharmacological inhibitor AMD3100 (Supplementary Fig. 18),
verifying CXCR4 dependency. Notably, msR4M-L1 dose-depen-
dently inhibited MIF-mediated DiI-oxLDL uptake, with complete
inhibition seen at a 3-fold molar excess of msR4M-L1 over MIF
(Fig. 4a, b). The uptake of oxLDL by macrophages is mediated by
scavenger receptors such as CD36, but studies in Cd36/Sra double
knockout mice suggest a role for additional pathways39.
As recent evidence suggested a contribution of native LDL
uptake to macrophage foam cell formation40 and as macrophage-
expressed CXCR4 promotes this process in a MIF/CXCR4- but
not CXCL12/CXCR4- specific manner41, we next tested the
capacity of msR4M-L1 to inhibit MIF-triggered uptake of
fluorescently labeled native LDL (DiI-LDL). Confirming previous
findings41, uptake of DiI-LDL by human macrophages was
enhanced by MIF in a CXCR4-dependent manner (Fig. 4c). Of
note, msR4M-L1 dose-dependently inhibited MIF-mediated DiI-
LDL uptake (Fig. 4c; Supplementary Fig. 19). Specificity of the
inhibitory effect was further confirmed by msR4M-L1(7xAla) and
msR4M-L1(2xAla), which failed to inhibit MIF-mediated DiI-
LDL uptake, as predicted from the binding and chemotaxis
experiments (Fig. 4d; Supplementary Fig. 16). The assay also
appeared suitable to compare the inhibitory capacity of msR4M-
L1 with that of established MIF inhibitors, i.e. the neutralizing
anti-MIF monoclonal antibody (mAb) NIH/IIID.9 and the small
molecule inhibitor ISO-1. The inhibitory capacity of msR4M-L1
was slightly better than that of ISO-1, but lower than that of NIH/
IIID.9 (Fig. 4e). This notion was confirmed by comparing the
binding affinity between msR4M-L1 and MIF with those of ISO-1
and anti-MIF mAbs. Neutralizing mAbs such as NIH/IIID.9 or
BAX01 bind human or mouse MIF with a KD of 1–2 nM16,42;
binding is thus more affine, albeit within a comparable
nanomolar range, than that between MIF and msR4M-L1 (≤40
nM). The KD for the MIF/ISO-1 interaction has not been
reported, but the IC50 value for MIF/CD74 binding is 10 µM16,43.
Using fluorescence spectroscopic titration, we determined the KD
between ISO-1 and MIF to be 14.4 ± 4.4 µM (Supplementary
Fig. 20). Thus, while msR4M-L1 is superior to ISO-1 and NIH/
IIID.9 in being receptor-selective, its inhibitory capacity and
binding affinity are between that of small molecule inhibitors and
anti-MIF mAbs.
We next tested the potency of msR4M-L1 towards MIF-elicited
three-dimensional (3D) chemotaxis of PBMCs. We applied 3D-
chemotaxis methodology and assessed single-cell migration tracks
via time-lapse microscopy. msR4M-L1 dose-dependently attenu-
ated MIF-triggered motility of human monocytes as quantified by
forward migration index. The pro-migratory effect of MIF was
already ablated by a 2-fold molar excess of msR4M-L1 (Fig. 4f, g,
i). By contrast, the CXCL12-induced cell motility response
remained unaffected (Fig. 4h, j).
A major atherogenic process promoted by MIF is its effect on
leukocyte adhesion in the atherosclerotic vasculature, an activity
involving engagement of CXCR414. To determine whether this
function of MIF can be attenuated by CXCR4 mimics, MIF-
triggered adhesion of MonoMac-6 monocytes on human aortic
endothelial (HAoEC) monolayers under static conditions was
assessed in the presence or absence of msR4M-L1. Figure 5a
shows that msR4M-L1 blocked the pro-adhesion effect of MIF.
Atherosclerosis is characterized by low-grade chronic inflamma-
tion in the vasculature with elevated levels of inflammatory
cytokines such as TNF-α. To account for this situation, we next
performed static adhesion on HAoECs prestimulated with TNF-
α. MIF also increased MonoMac-6 adhesion on TNF-stimulated
HAoECs, although the effect was less pronounced than in resting
HAoECs, and msR4M-L1 abrogated the effect of MIF (Fig. 5b).
To mimic physiological flow conditions, we next tested the
inhibitory capacity of msR4M-L1 in a flow adhesion setting
applying a shear stress of 1.5 dyn/cm2 to an HAoEC monolayer
super-fused with MonoMac6. Figure 5c shows that msR4M-L1
inhibited monocyte adhesion also under these hydrodynamic
flow conditions.
Before studying atherogenic leukocyte recruitment effects in
more pathogenically relevant ex vivo and in vivo settings, we wished
to determine whether msR4M-L1 localizes to atherosclerotic plaque
tissue. We stained plaque sections obtained from aortic root and
brachiocephalic artery of atherogenic Ldlr−/− and Apoe−/− mice,
respectively, with Fluos-msR4M-L1 to detect plaque binding of
the CXCR4 mimic. Fluos-msR4M-L1 positivity was significantly
more pronounced in plaque tissue from Mif-proficient atherogenic
Ldlr−/− or Apoe−/− mice when compared to sections from Mif-
deficient Ldlr−/− Mif−/− (Fig. 5d, e) or Apoe−/− Mif−/−
(Supplementary Fig. 21) mice, respectively. This showed that
Fluos-msR4M-L1, similar to anti-MIF antibody, was capable of
binding to plaque-associated MIF. We next tested whether
also in vivo administered Fluos-msR4M-L1 would localize
to atherosclerotic plaque. Three days before vessel preparation,
we intraperitoneally injected Fluos-msR4M-L1 into atherogenic
Apoe−/− mice. Multiphoton laser-scanning microscopy (MPM)
analysis of whole-mount carotid arteries from these mice visualized
by second harmonic generation (SHG) and fluorescein detection
revealed that Fluos-msR4M-L1 was markedly enriched in intimal
plaque areas (Fluos-msR4M-L1 positivity = 26.8 ± 1.4%; Fig. 5f, g).
A similar Fluos-msR4M-L1-positive area was detected in the aortic
root (25.0 ± 1.9%; Fig. 5g, h), suggesting together that the CXCR4
mimic is enriched, at least partially, in atherosclerotic plaques
in vivo.
To determine the functional consequence of this finding, we
studied leukocyte recruitment in ex vivo mounted atherogenic
carotid arteries using MPM. We injected mice with msR4M-L1
three days before vessel preparation and visualization of in situ
adhering msR4M-L1- versus vehicle-exposed fluorescently
labeled bone marrow-derived leukocytes in the vasculature under
physiological flow conditions (Fig. 5i). In fact, the mimic
significantly reduced the number of adhering leukocytes (Fig. 5j–l;
Supplementary Movie 1).
Together, these findings suggested that msR4M-L1 localizes
to atherosclerotic plaque tissue in a MIF-specific manner
and inhibits MIF-mediated atherogenic leukocyte recruitment
by interfering with chemotactic migration and arterial
adhesion.
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The engineered CXCR4 mimic reduces atherosclerosis in vivo.
Peptides are sensitive to proteolysis by plasma proteases and
clearance. Thus, before testing the potential therapeutic utility of
msR4M-L1 in vivo, we examined its proteolytic stability and
assessed its pharmacokinetic (PK) properties using fluorescently
and biotin-labeled analogs of the mimic. TAMRA-msR4M-L1
was incubated with mouse plasma for up to 48 h. SDS-PAGE
analysis and red fluorescence imaging (Fig. 6a) and densitometric
quantification of the TAMRA-msR4M-L1 band (Supplementary
Fig. 22) revealed that approximately 30% of intact TAMRA-
msR4M-L1 could be recovered upon 24–48 h of plasma exposure.
A similar result was obtained, when Biotin-6-Ahx-msR4M-L1
was incubated with human plasma isolated from the blood of
healthy donors (Supplementary Fig. 22), together indicating that
this peptide was reasonably stable in mouse and human plasma.
To assess the stability of msR4M-L1 in vivo, we i.p.-injected
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Number of tracks: 37, Counts left: 18, Counts right 19 Number of tracks: 33, Counts left: 2, Counts right 31 Number of tracks: 33, Counts left: 11, Counts right 22 Number of tracks: 34, Counts left: 14, Counts right 20 Number of tracks: 33, Counts left: 14, Counts right 19
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Fig. 4 msR4M-L1 specifically inhibits MIF- but not CXCL12-elicited atherogenic monocyte activities. a, b MIF-mediated DiI-oxLDL uptake in primary
human monocyte-derived macrophages is dose-dependently inhibited by msR4M-L1 (indicated as molar excess over MIF). MIF was applied at a
concentration of 80 nM. a Representative images of DiI-oxLDL-positive cells; b quantification (three-times-two independent experiments; 9 fields-of-view
each). c, dMIF-specific DiI-LDL uptake in primary human monocyte-derived macrophages is dose-dependently inhibited by msR4M-L1 (indicated as molar
excess over MIF) (c), but not by the MIF binding-dead analog of msR4M-L1, msR4M-L1(7xAla) (d). MIF was applied at a concentration of 80 nM.
Quantification (four-times-two or three-times-two plus one-time-three, respectively, independent experiments; 9 fields-of-view each). AMD3100 (AMD)
was used to verify CXCR4 dependence of the MIF effect. e Same as in c, d, except that the small molecule inhibitor ISO-1 and neutralizing MIF antibody
NIH/IIID.9 were used instead of msR4M-L1 (three-times-two independent experiments; 9 fields-of-view each; isotype control antibody IgG1: two-times-
two). f, g Representative experiment demonstrating that msR4M-L1 inhibits MIF-elicited (red tracks) 3D chemotaxis of human monocytes as assessed by
live-microscopic imaging of single-cell migration tracks in x/y direction in µm. Increasing concentrations of msR4M-L1 (blue tracks, molar excess over MIF)
as indicated; unstimulated control (gray tracks) indicates random motility. i Quantification of f, g; the migration tracks of 32–37 randomly selected cells per
treatment group were recorded and the forward migration index plotted; the experiment shown is one of three independent experiments with monocytes
from different donors. h A 5-fold molar excess of msR4M-L1 does not affect 3D human monocyte migration elicited by CXCL12; j quantification of h; the
migration tracks of 29–30 randomly selected cells per treatment group were recorded and the forward migration index plotted; the experiment shown is
one of two independent experiments with monocytes from different donors. Data in b–e, i, and j are reported as means ± SD. Statistical analysis was
performed with one-way ANOVA with Tukey’s multiple comparisons test or Kruskal–Wallis with Dunn’s multiple comparisons test. The scale bar in a is:
50 µm. CXCR4, CXC motif chemokine receptor-4; msR4M-L1, MIF-specific CXCR4 mimic-L1; MIF, macrophage migration-inhibitory factor. Source data are
provided as a Source Data file.
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TAMRA-msR4M-L1 into 8-week-old C57BL/6 mice (50 µg per
mouse or 2.5 mg kg−1) and obtained plasma at intervals between
0 and 48 h. SDS-PAGE analysis and fluorescence imaging of the
TAMRA-msR4M-L1 band revealed an appreciable in vivo stabi-
lity of the ectodomain mimic (Fig. 6b). Capitalizing on a
TAMRA-msR4M-L1 dose curve recorded in mouse plasma, we
estimated the plasma concentration of msR4M-L1. One hour
following i.p. administration, a plasma level of 180 ng mL−1 was
estimated, which declined by about 50% over the 48 h-time-
course (Fig. 6b; Supplementary Fig. 23).
To examine the therapeutic capacity of the CXCR4 mimic, we
employed an established in vivo mouse model of early
atherosclerosis, in which lesions develop in aortic root and arch
over a 4–5-week time course of HFD44. Apoe−/− mice received
msR4M-L1 (50 µg per mouse or 2.5 mg kg−1 i.p., three times per
week, dosing instructed by the above-determined in vivo stability)
or vehicle treatment in parallel to HFD for 4.5 weeks (Fig. 6c). We
did not observe any significant effect of msR4M-L1 administra-
tion on body weight, plasma total cholesterol, triglyceride levels,
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Fig. 5 msR4M-L1 localizes to atherosclerotic plaques in a MIF-specific way and inhibits atherogenic leukocyte arrest. a, b MIF-induced static adhesion
of MonoMac-6 monocytes to HAoECs is ablated by msR4M-L1. a Resting HAoECs. b As in a, except that HAoECs were pre-incubated with TNF-α.
Quantification based on 3 experiments with 10 independent fields-of-view each. c MIF-induced adhesion of MonoMac-6 monocytes to HAoECs under flow
conditions (1.5 dyn/cm2) is ablated by msR4M-L1. One of two independent experiments with four analyses each. d, e Fluos-msR4M-L1 stains aortic root
sections from atherogenic Ldlr−/−mice on HFD in a MIF-specific manner (comparison between Ldlr−/− and Ldlr−/−Mif−/−mice). d Representative images
(PC, phase contrast; DAPI, nuclei); e quantification (relative fluorescence units) from two independent experiments with two animals each indicates MIF-
specific staining. f, g Multiphoton laser-scanning microscopy image (f) of a carotid artery prepared from a hyperlipidemic Apoe−/− mouse, showing that
in vivo administered Fluos-msR4M-L1 localizes to atherosclerotic plaques. Vessel visualization by second harmonic generation (SHG). g Quantification of
the Fluos-msR4M-L1-positive area (means of n= 3 sections) as percentage of vessel target-area. h (and g) Same as f, g, except that aortic root was
prepared (green in upper panel is autofluorescence). Quantification in g indicates ORO-positive target-area. i–l msR4M-L1 inhibits leukocyte adhesion in
atherogenic carotid arteries under flow as analyzed by MPM. i Schematic summarizing the ex vivo leukocyte adhesion experiment. msR4M-L1 or vehicle
was injected before vessel harvest; flushed leukocytes are stained in red (msR4M-L1; CMPTX) or green (vehicle; CMFDA). j Representative image of a
carotid artery showing that pre-treatment with msR4M-L1 (red) leads to reduced luminal leukocyte adhesion compared to control (green), imaged by 3D
reconstruction after Z-stacking (0.8–1.5 µm) (blue: SHG). k Still image of a z sectioning video scan (single field of view) through the artery (morphology
revealed by SHG: collagen, dark blue; elastin, light blue). l Quantification of 5–6 independent carotid arteries per group. Luminally-adhering cell numbers
are plotted. Scale bars: d, 50 µm; f, 100 µm; h, 100 µm; j–k, 100 µm. Data in a, b, c, e, g and l are reported as means ± SD. Statistical analysis was performed
with one-way ANOVA with Tukey’s multiple comparisons test or two-tailed Mann–Whitney test as appropriate. The vessel icon in Fig. 5i was used with
permission from S. Karger AG (Copyright © 2006, © 2007 S. Karger AG, Basel78). msR4M-L1, MIF-specific CXCR4 mimic-L1; MIF, macrophage migration-
inhibitory factor. Source data are provided as a Source Data file.
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toward reduction in the msR4M-L1-treated group (Supplemen-
tary Table 3, Supplementary Fig. 24). Importantly, atherosclerotic
lesion size in aortic arch (Fig. 6d, e) and root (Fig. 6f, g) was
significantly decreased in msR4M-L1-treated mice compared with
vehicle-treated controls. Moreover, protection from lesion
formation was accompanied by a significantly decreased number
of lesional macrophages in the msR4M-L1 group, as revealed by
MAC-2 staining (Fig. 6 h, i), and by a marked reduction in
circulating inflammatory cytokine levels, as measured by a
cytokine array (Fig. 6j; Supplementary Fig. 25). Reductions in
the msR4M-L1-treated group were seen for IL-1α, IL-16, TNF-α
(Fig. 6j) as well as CXCL13/BLC (Supplementary Fig. 25), with
trends observed for IL-27, CCL12, IFN-γ, and TIMP-1, indicating
that the CXCR4 mimic broadly down-regulates the inflammatory
response associated with atherogenesis. Together, this demon-
strated that msR4M-L1 exhibits a therapeutic atheroprotective
and anti-inflammatory capacity in an experimental in vivo model
of atherosclerosis.
To further test the translational relevance of these findings, we
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Fig. 6 msR4M-L1 inhibits atherosclerosis in vivo and msR4M-L1-based staining parallels MIF expression in human plaques. a SDS-PAGE imaging of
TAMRA-msR4M-L1 mouse plasma incubations verifies proteolytic stability (red bands, TAMRA-msR4M-L1; green, running-dye). b In vivo stability of
msR4M-L1. TAMRA-msR4M-L1 i.p.-injected into C57BL/6 mice and plasma collected as indicated. The pharmacokinetic is derived from SDS-PAGE
TAMRA-msR4M-L1 bands (inset) applying a TAMRA-msR4M-L1 calibration curve (Supplementary Fig. 23). c Schematic showing the in vivo injection
regimen in atherogenic Apoe−/− mice. d, e msR4M-L1 treatment reduces atherosclerotic lesions in aortic arch. Representative images (d) and
quantification (e) of HE-stained sections from 7 msR4M-L1- versus 7 vehicle-treated mice. f, g msR4M-L1 treatment reduces lesions in aortic root.
Representative images (f) and quantification (g) of ORO-stained sections from 12 msR4M-L1- versus 12 vehicle-treated mice. h, i msR4M-L1 treatment
reduces macrophage content in aortic root. Representative images (h) and quantification of macrophage area (i) of anti-MAC2-stained (red) sections
from 11 msR4M-L1- versus 12 vehicle-treated mice. j msR4M-L1 reduces circulating inflammatory cytokines. Cytokine-array analysis of plasma samples
from 6 msR4M-L1- versus 6 vehicle-treated Apoe−/− mice on HFD (duplicates each) (means ± SD). k–m MIF gene expression is upregulated in
atherosclerotic plaques from CEA patients compared to healthy vessels but no difference between plaque stages. Expression measured with mRNA from
paraffin sections (k, qPCR, n= 19 stable and 20 unstable plaques, n= 4 healthy vessels) and mRNA from fresh tissue (l, qPCR, n= 9 early, n= 9 advanced
plaques; m, RNAseq, n= 6 stable and n= 5 unstable plaques). n–p Side-by-side-comparison (representative images) between anti-MIF antibody-based
IHC and TAMRA-msR4M-L1 staining for selected sections of stable CEA plaques (n, n= 6 sections, 11 specimens), unstable plaques (o, n= 2 sections,
15 specimens), and healthy vessel (p, n= 2 sections, 6 specimens); (left, overviews; right, magnifications of selected areas (boxes 1, 2) stained by anti-
MIF antibody (brown) and TAMRA-msR4M-L1 probe (red), DAPI+ (blue); circular arrow indicates DAB-/TAMRA-stained slides are not in same
orientation). Quantification of TAMRA-msR4M-L1-stained full cohorts in Supplementary Fig. 27b. Scale bars: d 50 µm; f 200 µm; h 200 µm; n–p 100 µm.
Data in e, g, i, and j are reported as means ± SD; data in k–m as box-whisker plots. Statistical analysis performed with unpaired two-tailed t-test (e, g, i, j),
two-tailed Mann–Whitney test, or Kruskal–Willis test (k, l, m) as appropriate. msR4M-L1, MIF-specific CXCR4 mimic-L1; MIF, macrophage migration-
inhibitory factor. Source data including definitions of box-plot parameters (minima, percentiles, centers, maxima) of k–m are provided as a Source Data file.
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from patients undergoing carotid endarterectomy (CEA). Based
on the histological characterization of plaque morphology and
availability of specimens for mRNA analysis, stable and unstable
plaques, and early versus advanced stage lesions were examined.
Healthy vessels served as additional controls (Supplementary
Table 4). MIF expression has been amply characterized in
atherogenic mouse models, but there is only limited information
on the quantification of MIF expression in human CEA lesions45.
We first profiled MIF mRNA expression from both paraffin-
embedded tissues and fresh plaque specimens by qPCR and RNA
sequencing (RNAseq). Quantitative PCR with mRNA extracted
from paraffin sections suggested that MIF expression was
markedly upregulated in both stable and unstable CEA plaques,
when compared to healthy control tissue (Fig. 6k). To further
characterize MIF expression in CEA plaques, fresh human tissue
specimens were studied by qPCR and RNAseq. These analyses
confirmed that MIF expression did not significantly differ
between early and advanced plaque stages (Fig. 6l, Supplementary
Fig. 26) or between stable and unstable plaques (Fig. 6m),
respectively. Selected specimens based on the mRNA expression
data were next applied for a side-by-side alignment of MIF
expression comparing immunohistochemical (IHC) staining of
MIF protein with an established antibody and staining with
TAMRA-msR4M-L1 as probe (Fig. 6n–p, Supplementary Figs. 27
and 28). Of note, staining with the CXCR4 mimic paralleled the
detection of MIF expression by IHC, exhibiting pronounced
staining of stable and unstable plaque tissue that was markedly
higher than TAMRA-msR4M-L1 positivity in healthy vessels
(Fig. 6n–p, respectively). Furthermore, quantification of TAMRA-
msR4M-L1 signals from stable and unstable plaque specimens
versus healthy vessel tissues was in line with the qPCR and
RNAseq-based expression pattern (Supplementary Fig. 28,
Fig. 6k–m). Moreover, MIF-specificity of the CXCR4 mimic-
derived probe was verified by a competition experiment with
peptide MIF(54–80), which is part of core binding region and
competes with MIF/msR4M-L1 binding (see Fig. 2h), and
significantly reduced stable plaque staining by TAMRA-
msR4M-L1 (Supplementary Fig. 28). Interestingly, previous work
had shown that CXCL12 exhibits more pronounced expression in
unstable compared to stable plaque46. Together, these findings
confirmed the significance of msR4M-L1/MIF binding in the
context of atherosclerotic plaque tissue from human CEA
specimens.
Discussion
Anti-cytokine/-chemokine strategies represent promising ther-
apeutic approaches for a variety of diseases, including cancer,
inflammation, and cardiovascular diseases. In addition to SMDs
and antibodies, soluble receptors are an important targeting
approach to block pathogenic cytokine effects7,47. While soluble
cytokine receptors have been developed for single-membrane-
spanning receptors and are successfully used in the clinic against
immune-mediated diseases, anti-chemokine strategies based on a
soluble receptor principle are not established.
Here we report on a small engineered peptide-based, soluble
chemokine receptor mimic that distinguishes between two che-
mokines and features ligand- and receptor-selective anti-athero-
sclerotic capacities in vitro and in vivo. We focused on CXCR4,
one of the most studied chemokine receptors48,49. CXCR4 has
critical ligand- and context-dependent roles in various diseases.
Together with its ligand CXCL12, it is a promising target in
tumor metastasis48 and small molecule CXCR4 inhibitors such as
Plerixafor/AMD3100 are used as stem cell mobilizers for trans-
plantation therapy of patients with specific cancers50. However, in
atherosclerotic diseases, the CXCR4/CXCL12 axis has proven to
be a difficult target, with both disease-promoting and protective
properties. Genome-wide association studies (GWAS) and
CXCL12 plasma level analysis revealed CXCL12 as a candidate
gene associated with CAD51–53, and disease-exacerbating activ-
ities such as cardiac inflammatory cell recruitment have been
implied for the CXCR4/CXCL12 axis54,55. In contrast, beneficial
activities include cardioprotective effects based on the contribu-
tion of CXCR4/CXCL12 to neoangiogenesis and cardiomyocyte
survival49,56,57. Moreover, disruption of this axis promotes
atherosclerotic lesion formation through deranged neutrophil
homeostasis58 and loss of atheroprotection26. In this context, we
have shown that atherogenesis-induced endothelial damage is
counter-acted by unleashing CXCR4 activity and autocrine
CXCL12 expression in endothelial cells through miR-126-
containing apoptotic bodies27 and that CXCR4 on vascular cells
maintains arterial integrity and limits atherosclerosis by preser-
ving barrier function and a normal contractile vascular smooth
muscle cell (VSMC) phenotype26.
Capitalizing on our earlier findings that CXCR4 engages MIF
as a non-cognate ligand to drive atherogenic leukocyte
recruitment14,16,17 and that CXCR4-supported endothelial barrier
integrity is mediated by CXCL12 but not MIF26, we surmised that
MIF-specific CXCR4 targeting might be a promising avenue to
circumvent the complexity of the CXCR4/CXCL12 system in
cardiovascular conditions. In fact, we previously demonstrated
that MIF-blocking strategies are superior to CXCL12 blockade in
inducing plaque regression6,14 and that a native LDL/LDL
receptor (LDLR)-based foam cell-promoting activity of CXCR4 is
primarily elicited by MIF and not CXCL1241. However, currently
available MIF-blocking strategies may not be optimal, as anti-MIF
(Imalumab) or anti-CD74 (Milatuzumab) antibodies would
potentially interfere with the cardioprotective MIF/CD74
axis15,16. The same holds true for MIF-directed SMDs, which are
designed to bind in MIF’s conserved tautomerase pocket and
interfere with MIF binding to CD74. Indeed, modification of this
cavity invokes conformational changes in MIF that impair
binding to CD7459. AMD3100 partially interferes with MIF/
CXCR4 binding14,25, but this CXCR4 inhibitor has been found to
impair the cardio- and atheroprotective activity spectrum of the
CXCR4/CXCL12 axis26,27,58.
Our design was guided by the CXCR4 structures29–31 and SAR
studies24,25, highlighting CXCR4 ectodomain regions that may be
harnessed to engineer a soluble receptor mimic to selectively target
MIF and spare CXCL12. Approaches to utilize the ectodomains of
single-membrane-spanning type I cytokine receptors such as the
TNF or IL-6 receptor have been successfully developed as
immunomodulatory drugs7,47. However, mimicking the ectodo-
main of seven-helix membrane-spanning GPCRs is inherently
complex due to the discontinuous nature of the receptor backbone
topology. Ligand binding in (poly)peptide-ligating GPCRs such as
chemokine receptors typically involves several extracellular por-
tions of the receptor, often a combination of residues of several
ECLs and the N-terminal30. Only a handful of reports are avail-
able: the N-terminal and ECL3 elements of CXCR1 and CXCR2
were assembled on a soluble GPCR B1 domain scaffold protein60;
based on the crystal structure of rhodopsin, all three predicted
ECLs of CXCR4 were connected to form an HIV gp120-binding
mimic61; and a construct mimicking corticotropin-releasing factor
receptor-1 (CRF-R1) combined native chemical ligation and
recombinant technology and encompassed the entire 23 kDa
ectodomain of CRF-R162. Such studies have remained explorative,
led to constructs with micromolar binding affinities, and neither
chemokine selectivity nor in vivo or disease relevance were
addressed.
The engineered MIF-selective CXCR4 mimics reported here
are highly reduced GPCR mimics of only 29 residues plus two
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non-natural amino acids of the linker moiety (molecular weight
<4 kDa), reducing the size of CXCR4 by >90%. MIF selectivity
over CXCL12 was achieved by combining only selected residues
within ECL1 and ECL2. As determined by independent biophy-
sical methods such as fluorescence spectroscopy, FP, and MST,
the lead candidate mimics bind MIF with low nanomolar affinity
(KD ~ 20–75 nM), in line with the reported KD value of 19 nM for
MIF binding to full-length membrane CXCR414, while binding to
CXCL12 is essentially absent. This affinity is reasonable compared
with that of Imalumab or the pre-clinical anti-MIF antibody
NIH/III.D9 (KD ~ 1–3 nM)63 and MIF-directed SMDs (micro-
molar KD)16. Of note, msR4M-L1 neither affected MIF binding to
CD74 as indicated by FP and MST, nor did it impair MIF/CD74-
mediated stimulation of AMPK phosphorylation in human car-
diomyocytes as a correlate of MIF’s cardioprotective activity15.
Hence, msR4M-L1 has more favorable selectivity characteristics
than the available anti-MIF therapeutic strategies. A molecular
explanation for this selectivity comes from experiments mapping
the MIF binding site by MIF peptide fragments and a site-specific
mutant. msR4M-L1 targets MIF region 54–80, a part of the N-like
loop known to mediate MIF/CXCR4 binding, but not involved in
MIF/CD74 binding, in line with data showing that the tauto-
merase site of MIF, Tyr-100, and residues 80–87 determine the
MIF/CD74 binding interface21,22,59. Importantly, binding selec-
tivity of msR4M-L1 for MIF versus CXCL12 was functionally
paralleled in a number of inflammation- and atherosclerosis-
relevant cell systems, i.e. GPCR/CXCR4 signaling, 2D lymphocyte
chemotaxis, foam cell formation, monocyte adhesion under static
and flow conditions, and 3D monocyte migration, together
representing MIF/CXCR4-mediated cell systems with disease
relevance41.
Mapping of the binding site of the CXCR4 mimic by alanine-
scanning pinpointed a role for the aromatic residues within
msR4M-L1, in particular Phe-104 and Phe-107, and also offered
additional proof for the specificity of the MIF/msR4M-L1 binding
mechanism. Interesting structural information also comes from
mimics, in which we introduced a disulfide bridge between resi-
dues Cys-109 of ECL1 and Cys-186 of ECL2. In contrast to
msR4M-L1 and -L2 that are fully selective for MIF, introduction
of the disulfide bridge led to a gain-of-CXCL12-binding activity,
irrespective of the presence (msR4M-L1ox, msR4M-L2ox) or
absence (msR4M-LS) of the spacer-mediated conformational
constraint. This is in line with the previously identified Cys-109-
Cys-186 disulfide in the X-ray structure of CXCR429,30 and
existing knowledge on the CXCR4/CXCL12 interface64, and
supports the notion that the natural CXCR4 receptor is ‘equip-
ped’ to interact with both CXCL12 and MIF14. On the other
hand, the KD for MIF binding dropped >10-fold, when the
respective ECL1 and ECL2 sequences were not covalently linked.
Together, these data reveal that while the herein identified aro-
matic residues and the conformational restriction imposed on
ECL1 and ECL2 are required for MIF binding, a certain degree of
conformational flexibility is necessary to guarantee selectivity
between different CXCR4 chemokines. Comparison of the var-
ious synthesized mimics further instructs for future optimization
towards higher potency, stability, or selectivity28.
The biochemical and cell-based experiments encouraged us to
examine whether the mimics would be efficacious in a pathogenic
ex vivo organ or in vivo setting. Using fluorescently labeled
msR4M-L1 to stain atherosclerotic tissue sections from athero-
genic mice and in vivo administration of labeled peptide verified
that msR4M-L1 localizes to atherosclerotic plaque tissue in a
MIF-specific manner. Indeed, MIF has been shown to be upre-
gulated in atherosclerotic lesions, where secreted MIF is deposited
similar to classical arrest chemokines and localizes to plaque
macrophages, foam cells, and VSMCs14,45,65. While these
experiments do not fully exclude the possibility that msR4M-L1
also -partially- localizes to CXCL12+ regions, our biochemical
data proving binding selectivity, suggest that this is unlikely.
Furthermore, while the MIF homolog MIF-2/D-DT13 has not
been studied in atherosclerosis, it may be of future interest to
design mimics directed at MIF-2 for applications in MIF-2-
dominated inflammatory conditions.
We used an MPM-based ex vivo atherosclerotic carotid artery
system to monitor luminal leukocyte adhesion under pathophy-
siologically relevant conditions and demonstrated that treatment
with msR4M-L1 markedly attenuated adhering leukocyte num-
bers. Such systems have been powerful in demonstrating the
leukocyte recruitment potential of MIF or classical arrest che-
mokines such CXCL1/KC14,44,58,66,67. In conjunction with the
Fluos-msR4M-L1 plaque staining data, the MPM data indicate
that msR4M-L1 blocks MIF-mediated atherogenic leukocyte
recruitment. Important proof for a translational utility of the
GPCR mimics reported here comes from testing msR4M-L1
therapeutically in a mouse model of atherosclerosis in vivo44. The
chosen treatment regimen of three 50 µg-injections per week was
instructed by plasma proteolytic and in vivo stability data that
indicated reasonable plasma levels of msR4M-L1 in the range of
20–50 nM up to two days after injection, maintaining circulating
doses of the mimic overall in line with the determined KD/IC50
values. The mimic potently blocked atherosclerosis at key pre-
dilection sites, reduced lesional macrophage accumulation and
circulating inflammatory cytokines/chemokines, while no effects
on lipids or leukocyte counts were observed, suggesting that it
specifically targeted a MIF-mediated pathogenic inflammatory
effect in atherogenic lesions. The experiment constitutes a ‘proof-
of-concept’ for such compounds in an in vivo disease setting and
is a good predictor for their efficacy in advanced atherosclerosis
models, but also other models involving MIF-related chronic
inflammation12,14,16,17,58,68. Moreover, CXCR4 is a major
receptor driving cancer metastasis, and not only the CXCR4/
CXCL12 but also the CXCR4/MIF axis has been implicated in this
process48,69. While it is beyond the scope of this study to address
the inhibitory potential of our peptides in cancer, the mimics
appear principally suitable for such an application. Further, the
selectivity differences seen between our covalently linked con-
formationally restricted versus non-linked versus hyper-restricted
constructs may instruct for the design of dual-specificity inhibi-
tors against both MIF and CXCL12, e.g. for future applications in
cancer. Similarly, it may be envisaged to expand the concept to
MIF/CXCR2, which also has a role in atherosclerosis1,14.
The CANTOS trial has provided clinical proof that an
immunotherapy-based targeting approach against IL-1β, a key
inflammatory mediator, improves cardiovascular outcome in an
at-risk population4,70. However, treatment with Canakinumab
did not improve mortality in atherosclerotic patients and caused
an increase in infections, highlighting the need to identify addi-
tional drug targets and to develop anti-inflammatory strategies
with a high selectivity profile that block atherosclerotic pathways.
Engineering of CXCR4 mimics specifically targeting MIF/CXCR4
interactions could be one such approach and represent a pro-
mising class of anti-atherogenic molecules based on the applied
soluble GPCR ectodomain concept. MsR4Ms are peptide-based
molecules and, while there are over 60 peptide drugs approved
worldwide, there are pros and cons compared to antibodies and
SMDs. Advantages are good surface coverage and hence high
selectivity and potency, favorable safety, and low-cost production;
disadvantages are the limited proteolytic stability and bioavail-
ability71. However, these issues can be overcome by peptide
chemistry tools and peptide design strategies28,71. Thus, msR4M-
L1 should be viewed as a proof-of-concept inhibitor of MIF/
CXCR4-specific atherogenesis, whose properties may be
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improved by designed second-generation mimics. Of note,
despite the many inherent differences between the experimental
atherosclerosis mouse model applied herein and future clinical
applications and the numerous unforeseeable risks along any
drug development pipeline, the in vivo msR4M-L1 dose and
application frequency used in our study overall appears to be
compatible with a potential optimization route towards an effi-
cacious drug. Accordingly, studies in patients with atherosclerotic
disease could be a future perspective. In fact, TAMRA-msR4M-L1
staining of human carotid artery samples from patients who
underwent CEA mirrored the high MIF expression profile in both
stable and unstable plaque lesions versus healthy vessels as
detected by qPCR, RNAseq, and antibody staining, but differs
from the expression profile of CXCL12 as previously determined
by qPCR46.
In conclusion, the designed MIF-selective soluble CXCR4
mimics are a previously unrecognized class of anti-athero-
sclerotic/-inflammatory agents that could complement currently
available inhibition strategies by antibodies or SMDs. We
demonstrate that these molecules can be engineered to be che-
mokine-selective, to exhibit high binding affinities, and to be
potent in blocking atherogenic chemokine activities in vitro and
in vivo, while sparing potentially contraindicative protective
pathways through alternative receptors or ligands.
Methods
Cytokines/chemokines and reagents. Biologically active recombinant MIF was
prepared by expression in the pET11b/E. coli BL21/DE3 system, recovery of the
supernatant of the bacterial lysate, centrifugation, filtration, purification by Mono
Q anion exchange and C8 reverse-phase chromatography, and dialysis-based
renaturation and exhibited a purity of ∼98%. The details of this procedure are
described in references14,36. For some of the biophysical methods, a 90–95%
purified preparation was used. Fluorescently labeled MIF18 (Alexa-488-MIF or
Alexa-647-MIF) was generated using Microscale Protein Labeling Kits from
Invitrogen-Molecular Probes (Karlsruhe, Germany; Alexa-488/A30009, Alexa-647/
A30009). LPS content was tested by limulus amoebocyte assay (LAL, Lonza,
Cologne, Germany) and verified to be <5 pg µg−1. Mutant [A47–56]-MIF or MIF
(10xAla) was generated by PCR cloning using the cDNA sequence of wildtype
human MIF (WT-MIF) as template and the sequence verified by DNA sequencing.
Bacterial expression and purification of MIF(10xAla) were performed following the
established protocol for WT-MIF36, except that pET29b was used and the bacterial-
expressed protein initially recovered from inclusion bodies. Cell culture-grade
tumor necrosis factor (TNF)-α was purchased from Life Technologies (Carlsbad,
United States). Recombinant CXCL12 was a gift of Dr. von Hundelshausen (LMU
Munich)67 or was purchased from Peprotech (Hamburg, Germany). Other
reagents were obtained from Sigma, Merck, Roth, or Calbiochem, and were of the
highest purity degree available.
Peptide design, peptide synthesis, purification, and linker chemistry. Based on
the crystal structures of human CXCR4 (accession codes 3ODU; 3OE0; 3OE6;
3OE8; 3OE9; 4RWS and previous SAR studies24,25, CXCR4 ectodomain peptides
were selected. The crystal structures were imported into PyMOL Molecular Gra-
phics System (Version 1.8.2.2 Schrödinger, LLC) and Jmol (http://www.jmol.org)
for determining the C-to-N distance between residues 97–110 and 182–19629,30.
Conjugates of 12-Ado with either 6-Ahx or O2Oc were visualized in three-
dimensional space using Molview and Jmol. The estimated distances between the
N- and C-terminal in both conjugates were similar to the ECL1-ECL2 distance. All
CXCR4-derived peptides, including msR4M-L1(7xAla) and msR4M-L1(2xAla),
were synthesized as C-terminal amides on Rink amide MBHA resin by SPPS using
Fmoc chemistry28. Couplings of Fmoc-6-Ahx-OH, Fmoc-12-Ado-OH and Fmoc-
O2Oc-OH (Iris Biotech GmbH, Marktredwitz, Germany) were carried out with 3-
fold molar excess of 2-(7-Aza-1H-benzotriazole-1-yl)- 1,1,3,3-tetramethyluronium
hexafluorophosphate (HATU) and 4.5-fold molar excess of N,N-diisopropylethy-
lamine (DIEA) in N,N-dimethylformamide (DMF). Fmoc-deprotection was in
general carried out with 0.1 M hydroxybenzotriazole (HOBt) in 20% v/v piperidine
in dimethylformamide (DMF) for 3 and 9 min to avoid aspartimide formation32.
To introduce Nα-fluorescein and TAMRA labels, 5(6)-carboxyfluorescein-N-
hydroxysuccinimide ester (Sigma-Aldrich, Taufkirchen, Germany) and 5(6)-car-
boxytetramethylrhodamine (TAMRA, Novabiochem/Merck KGaA, Darmstadt,
Germany) were coupled N-terminally to side chain-protected msR4M-L1 on solid
phase, after Fmoc-deprotection32. The Nα-biotinyl label was introduced as follows:
after assembly of fully protected msR4M-L1 and Nα-Fmoc-cleavage, Fmoc-
protected 6-Ahx was coupled followed by Fmoc-cleavage and coupling of biotin
using the coupling protocols as above32. Disulfide bridges in msR4M-L1ox and
msR4M-L2ox were formed in 1 mgmL−1 peptide solution in aqueous 3M gua-
nidinium hydrochloride (GdnHCl) and 0.1 M ammonium carbonate (NH4HCO3)
solution, containing 40% dimethylsulfoxide (DMSO). msR4M-LS was produced
similarly, using 0.3 mg mL−1 ECL1 and 0.5 mgmL−1 ECL2 and 20% DMSO.
Reverse-phase high-performance liquid chromatography (RP-HPLC) was applied
for the purification of crude and oxidized peptides by using Reprosil Gold 200 C18
(250×8 mm) or Reprospher 100 C18-DE (250 × 8mm) columns with pre-column
(30×8 mm) (Dr. Maisch-GmbH, Herrenberg, Germany). The mobile phase con-
sisted of 0.058% (v/v) trifluoroacetic acid (TFA) in water (buffer A) and 0.05%
(v/v) trifluoroacetic acid in 90% (v/v) acetonitrile and water (buffer B) (flow rate
2.0 mL/min). All peptides were purified with an elution program of 10% B for 1
min, followed by a gradient from 10 to 90% B over 30 min, except for msR4M-LS,
which was eluted with 30% B for 7 min followed by an increase to 60% B over 30
min. Expected molecular weights were verified by matrix-assisted laser desorption/
ionization mass spectrometry (MALDI-MS). Peptides were used as TFA salts. For
in vivo experiments, the TFA anion was exchanged to chloride by four cycles of
dissolution/lyophilization of pure msR4M-L1 in aqueous 5 mM HCl and one cycle
of bidistilled water. MIF sequence-based peptides (Supplementary Table 2) were
synthesized on Wang resin or purchased from Peptide Specialities GmbH (PSL,
Heidelberg, Germany). MIF-derived peptides were N-terminally acetylated and
their C-terminal end is a free carboxylate.
Fluorescence spectroscopy. Fluorescence spectroscopic titrations were performed
using a JASCO FP-6500 fluorescence spectrophotometer. MIF, MIF(10xAla), or
CXCL12 were reconstituted in 20 mM sodium phosphate buffer, pH 7.2; peptide
stocks including those of MIF fragments were freshly made in 1,1,1,3,3,3-hexa-
fluoro-2-propanol (HFIP) at 4 °C at a concentration of 1 or 2 mM28,32. After
adding Fluos-labeled peptides or Alexa-488-MIF and their unlabeled titration
partner in assay buffer and a subsequent mixing step, measurements were per-
formed in 10 mM sodium phosphate buffer, pH 7.4, containing 1% HFIP. Fluos-
labeled peptide was applied at 5 nM and Alexa-488-MIF at 10 nM unless indicated
otherwise. For the titration with ISO-1, Alexa-488-MIF had a concentration of 50
nM and ISO-1 was varied from 0.1 to 500 μM in 10mM sodium phosphate buffer,
pH 7.4, containing 0.5% DMSO. The excitation wavelength was 492 nm and
emission spectra were obtained between 500 and 600 nm. Apparent KD values
(app. KD) were calculated assuming a 1/1 binding model using sigmoidal curve
fittings with OriginPro 2016 (OriginLab, Northampton, MA, USA) or GraFit 5
(Erithacus Software Ltd., Wilmington House, UK) data analysis software as
appropriate32.
Circular dichroism (CD) spectroscopy. CD spectra were obtained with a JASCO
J-715 spectropolarimeter (JASCO, Tokyo, Japan) applying an established proto-
col72. Briefly, far-UV CD measurements were carried out between 195 and 250 nm.
The response time was set at 1 s, intervals at 0.1 nm, and bandwidth at 1 nm. All
spectra were measured at RT and represent an average of three recorded spectra.
Scans were recorded for the ectodomain mimic peptides at a concentration of 1–20
µM in 10 mM sodium phosphate buffer, pH 7.4, containing 1% HFIP, following
dilution of freshly made peptide stock solution in HFIP (4 °C) into the buffer-
containing cuvette. Singular ECL1 and ECL2 peptides were measured at 5 µM. The
background spectrum of buffer/1% HFIP alone was subtracted from the spectra of
the peptides. Dynode voltage was below 1000 and did not interfere with the
measurements.
Fluorescence polarization. FP was measured with a JASCO FP-6500 fluorescence
spectrophotometer equipped with FDP-223 and FDP-243 polarizers. Stock solu-
tions for peptides, MIF, and CXCL12 were prepared as described above under
fluorescence spectroscopy. Final mixtures between Fluos-msR4M-L1 (5 nM) and
non-labeled MIF (titrated from 0.5 to 277.5 nM) or CXCL12 (varied from 5 nM to
2.5 µM) were measured in 10 mM sodium phosphate, pH 7.2, containing 0.5%
HFIP. Alexa-488-MIF (10 nM) and unlabeled peptide (titrated from 0.5 nM to 1
µM) was measured in 10 mM sodium phosphate, pH 7.2, containing 2% HFIP.
Experimental conditions were similar for the titrations between Alexa-488-MIF
and soluble human CD74 (sCD74). Soluble CD7419 is a fusion protein of an N‐
terminal HA-tag and CD74 residues 73–232 (R&D Systems, Minnesota, USA). The
sCD74 stock solution (26 μM) was prepared in PBS, pH 7.2. Alexa-488-MIF was
prepared in 20 mM sodium phosphate buffer, pH 7.2. For binding analyses, 10 nM
Alexa-488-MIF and the respective sCD74 sub-stocks were mixed in 10 mM sodium
phosphate, 2% HFIP, 0.01 × PBS, and incubated at RT for 4 h. For competition
experiments with msR4M-L1, Alexa-488-MIF was briefly pre-incubated with a 20-
fold molar excess of msR4M-L1, and the mixture titrated against sCD74 as above.
Bandwidth for excitation and emission was set at 5 nm and time response at
0.5 s. The excitation wavelength was 492 nm and emission was recorded at 519 nm.
Measurements were performed at RT and within 2–3 min upon preparation of the
solutions. Polarization was calculated using the equation: P= (Iǁ − G·I⊥) / (Iǁ+
G·I⊥), in which Iǁ is the intensity of emitted light polarized parallel to the excitation
light, I⊥ is the intensity of emitted light polarized perpendicular to the excitation
light, and the G factor was calculated based on the instrumental documentation
(https://currentprotocols.onlinelibrary.wiley.com/doi/10.1002/9780470559277.
ch090102. Apparent KD values (app. KD) were calculated assuming a 1/1 binding
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model, using sigmoidal curve fittings with OriginPro 2016 (OriginLab) or GraFit 5
(Erithacus Software Ltd.) data analysis software as appropriate32.
Dot blot. Different amounts (0–400 ng) of human MIF, mouse MIF, or human
CXCL12 were spotted on a nitrocellulose membrane and membranes allowed to
dry for 30 min. Non-specific binding was blocked with Tris-buffered saline (TBS),
pH 7.4, containing 0.1% Tween-20 (TBS-T) and 1% BSA. TAMRA-msR4M-L1 was
reconstituted at a concentration of 10 µM in PBS containing 2.5% HFIP, diluted to
a 3 µM working solution in 1% BSA/TBS-T, and incubated with the membrane at
4 °C. For the competition experiment, TAMRA-msR4M-L1 was incubated in the
presence of a 2-fold molar excess of MIF peptide fragment MIF[54–80]. Fluores-
cence intensities were measured at 600 nm using an Odyssey® Fc imager (LICOR
Biosciences, Bad Homburg, Germany). The total intensity of each spot was auto-
matically corrected by the individual background signal. The signal intensity of
400 ng human MIF was set to 100%.
Microscale thermophoresis. MST measurements were recorded on a Monolith
NT.115 instrument with green/red filters (NanoTemper Technologies, Munich,
Germany). MST and LED power were set 80 and 95%, respectively. All measure-
ments were performed at 37 °C. MST traces were tracked for 40 s (laser-off: 5 s,
laser-on: 30 s; laser-off: 5 s). A stock solution of 200 nM TAMRA-msR4M-L1 was
prepared in 20 mM sodium phosphate buffer, pH 7.2, containing 0.2% Tween-20.
For titration of MIF, sub-stock solutions were prepared by serial 1:1 dilutions from
a 20 µM stock solution in 20 mM sodium phosphate buffer, pH 7.2. TAMRA-
msR4M-L1 (final concentration: 100 nM) and each MIF sub-stock were mixed at a
1:1 ratio, incubated for 10 min and loaded in the capillaries. Data points/MST
traces were analyzed at an MST-on time of 1.5 s using the MO.Affinity Analysis
v2.2.4 (NanoTemper Technologies). The same conditions were used for analyzing
titrations between TAMRA-msR4M-L1 (100 nM) and CXCL12.
Experimental conditions were similar for the titrations between Alexa-647-MIF
and soluble human CD74 (sCD74), except that LED power was set at 80%. The
sCD74 stock solution (26 μM) was prepared in PBS, pH 7.2, and then further
diluted in 10 mM Tris and 0.5 × PBS, containing 0.01% BSA. The Alexa-647-MIF
stock was 40 nM in 10 mM Tris buffer, pH 8.0. For binding analyses, Alexa-647-
MIF was mixed 1:1 with the respective sCD74 sub-stocks and mixtures incubated
at RT for 3 h and 37 °C for 15 min prior to analysis at the same temperature. Data
analysis was based on the signal of an MST-on time of 30 s. For competition
experiments with msR4M-L1, 40 nM Alexa-647-MIF was pre-incubated with 400
nM msR4M-L1 for 10 min, and the mixture titrated against sCD74 as above.
App. KD values were calculated assuming a 1/1 binding model, using sigmoidal
curve fittings with OriginPro 2016 (OriginLab) or GraFit 5 (Erithacus Software
Ltd.) data analysis software as appropriate32.
Peptide spot array technology and alanine-scanning. Peptides were generated
by stepwise SPOT synthesis on modified cellulose disks (Intavis MultiPep RSi/
CelluSpot Array, Cologne, Germany) essentially as described previously24. Briefly,
peptides were processed, cellulose dissolved, and spotted onto coated glass slides
using an Intavis Slide Spotting Robot. Glass microarrays were blocked in 50 mM
Tris-buffered saline (TBS) containing 0.1% Tween 20 and 1% BSA and washed in
TBS containing 0.1% Tween 20. The array was probed with 3 µM biotinylated
human MIF and developed with horse-radish peroxidase (HRP)-conjugated
streptavidin in blocking buffer. For the determination of false-positives, a control
array was incubated with HRP-conjugated streptavidin alone. Chemiluminescent
signals were measured by Odyssey® Fc imager. The intensity of each spot was
corrected for spot-specific background signal and normalized to the intensity of the
wildtype peptide.
CXCR4-specific signaling in a yeast-based cell system. The yeast CXCR4-
specific cell signaling system employing S. cerevisiae strain (CY12946), expressing
functional CXCR4 that replaces the yeast STE2 receptor and is linked to a β-
galactosidase (lacZ) signaling read-out, was used, as CXCL12 and MIF elicit a
CXCR4-specific signaling response in this cell system24,25. Briefly, yeast transfor-
mants stably expressing human CXCR4 were grown overnight at 30 °C in yeast
nitrogen base selective medium (Formedium, UK). Cells were diluted to an OD600
of 0.2 and grown to an OD600 of 0.3–0.6. Transformants were incubated with
20 µM human MIF or 2 µM human CXCL12 in the presence or absence of different
concentrations of msR4M-L1 for 1.5 h. OD600 was measured and activation of
CXCR4 signaling quantified by β-galactosidase activity using a commercial BetaGlo
Kit (Promega, Mannheim, Germany).
Cell culture and cell lines. Human aortic endothelial cells (HAoECs) were from
PromoCell (Heidelberg, Germany). Cells were plated on collagen (Biochrom AG,
Berlin, Germany) in endothelial cell growth medium (ECGM, PromoCell) and
cultured according to the manufacturer’s recommendations and as described
previously73. The monocytic cell line MonoMac-6 was cultured in RPMI 1640
medium with 10% fetal calf serum (FCS). Primary human cardiac myocytes
(HCM) isolated from the ventricles of the adult heart were from PromoCell and
used at passage 2–8. They were cultured in myocyte basal medium (PromoCell),
containing 5 µg mL−1 insulin, 5% FCS, 2 ng mL−1 fibroblast growth factor (FGF),
and 0.5 ng mL−1 epidermal growth factor (EGF). Human embryonic kidney
(HEK)-293 cells were cultured in DMEM-GlutaMAX (Life Technologies-Gibco)
supplemented with 10% FCS and 1% penicillin/streptomycin. FCS was obtained
from Invitrogen-Thermo Fisher Scientific. Miscellaneous cell culture reagents
(media, supplements) were bought from Invitrogen and PAA (Pasching, Austria).
HEK293-CD74 surface binding assay. HEK293 cells were transiently transfected
with 8 µg of the pcDNA3.1-CD74minRTS-FLAG plasmid using Polyfect (Qiagen,
Hilden, Germany) and expressed surface CD74 after 24 h (efficiency 50–60%) in
line with previous data74. HEK293-CD74 transfectants were washed and 3 × 105
cells resuspended in ice-cold PBS containing 0.5% BSA, and incubated with 400
nM Alexa-488-labeled MIF in the presence or absence of msR4M-L1 (2 µM) on ice
for 2 h. After washing in ice-cold PBS containing 0.1% BSA, the amount of Alexa-
488-labeled MIF bound to the cell surface was quantified by flow cytometry using a
FACS Verse instrument (BD Biosciences, Heidelberg, Germany). Binding of Alexa-
488-MIF to non-transfected wildtype HEK293 cells, which do not express CD74,
served as background control.
Mice. Mice were housed under standardized light-dark cycles in a temperature-
controlled air-conditioned environment under specific pathogen-free conditions at
the Center for Stroke and Dementia Research (CSD), Munich, Germany, with free
access to food and water. All mice used in this study were between 7 and 10 weeks
of age and were on C57BL/6 background. Apoe−/− mice were initially obtained
from Charles River Laboratories (Sulzfeld, Germany) and backcrossed within the
CSD animal facility before use. The atherogenic Ldlr−/− and Ldlr−/− Mif−/− mice
as well as Apoe−/− Mif−/− mice have been described previously14,66. All mouse
experiments were approved by the Animal Care and Use Committee of the local
authorities (Regierung von Oberbayern, ROB; Aktenzeichen Az = ROB-55.2Vet-
2532.Vet_02–18–40) and performed in accord with the animal protection repre-
sentative at the Center for Stroke and Dementia Research (CSD).
Chemotaxis analysis of murine B cells. A Transwell-based assay was used as
described previously35. Briefly, splenic B cells were isolated by negative depletion
using a Pan B Cell Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany).
Purity of the cells was between 95 and 99%. One-hundred µL of cell suspension
containing 1 × 106 cells in RPMI 1640/5% FCS was loaded into the upper chamber
of a Transwell insert. Filters were transferred into the lower chambers containing
MIF or CXCL12 in the presence or absence of ectodomain peptides. Chemotaxis
was followed for 4 h at 37 °C in a humidified atmosphere of 5% CO2. Migrated cells
were counted by flow cytometry using CountBright™ Absolute Counting Beads
(Molecular Probes-Invitrogen).
CD74 signaling in human cardiomyocytes. HCMs (2 × 105 per well) were plated
in 12-well plates and maintained for 2 days with cultured medium containing 5%
FCS. Before stimulation, medium was replaced by fresh myocyte basal medium
containing 0.05% FCS and HCMs rested for 16 h. Surface CD74 expression on
HCMs was verified by flow cytometry (FITC-conjugated anti-human CD74 (1:100
dilution), FITC-IgG2 (isotype control) (BD Pharmingen), 1 h/4 °C in the dark, BD
FACSVerse™ flow cytometer, FlowJo software). AMPK signaling was elicited by
addition of 16 nM of human MIF and incubation at 37 °C for 60 min. To test for an
influence of msR4M-L1, MIF was pre-incubated with 16 or 80 nM msR4M-L1 and
mixtures added to HCMs. After treatment, cells were lysed and subjected to SDS-
PAGE (10%)/Western blotting using NuPAGE® lithium dodecyl sulfate (LDS)/
dithiothreitol (DTT) lysis buffer-containing PhosSTOPTM reagent (Roche Applied
Science). AMPK activation was revealed with an antibody against phosphorylated
AMPK (anti-pAMPKα, 1:1000, Cell Signaling Technologies, Heidelberg, Germany)
and total AMPKα (anti-AMPKα, 1:1000), as well as actin detected for standardi-
zation. Anti-rabbit horse-radish peroxidase (HRP)-conjugated antibody (1:10000,
GE Healthcare, Freiburg, Germany) was used for development and signals quan-
titated by chemiluminescence using an Odyssey® Fc imager. Unprocessed scans of
the Western blots are supplied in the Source Data file.
Isolation of human peripheral blood-derived monocytes. Human peripheral
blood-derived monocytes were isolated following an established procedure14.
Briefly, blood was collected from healthy donors or buffy coat obtained from the
blood bank of LMU University Hospital, mixed 1:1 with PBS, and PBMCs isolated
by Ficoll-Paque Plus gradient (GE Healthcare). Monocytes were purified by
negative depletion using the Monocyte Isolation Kit II (Miltenyi). Monocyte purity
was verified by flow cytometry using an anti-CD14 antibody (Miltenyi) and was
95–98%. Purified cells were suspended in RPMI 1640 medium supplemented with
10% FCS, 1% penicillin/streptomycin, 2 mM L-glutamine and 1% NEAA. The
isolation of PBMCs from donor blood was approved by the local ethics committee
of LMU Munich.
3D migration of human peripheral blood-derived monocytes by time-lapse
microscopy. The 3D-migration behavior of human monocytes was assessed by
time-lapse microscopy and individual cell tracking using the 3D chemotaxis µ-Slide
system from Ibidi GmbH (Munich, Germany), adapting the established Ibidi
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dendritic cell protocol for human monocytes. Briefly, isolated monocytes (4 × 106
cells) were seeded in rat tail collagen type-I gel in DMEM and subjected to a
gradient of MIF or CXCL12 (64 nM) in the presence or absence of msR4M-L1. Cell
motility was monitored performing time-lapse imaging every 1 min at 37 °C for 2 h
using a Leica inverted DMi8-Life Cell Imaging System equipped with a DMC2900
Digital Microscope Camera with CMOS sensor and live cell-imaging software
(Leica Microsystems, Wetzlar, Germany). Images were imported as stacks to
ImageJ software and analyzed with the manual tracking and chemotaxis/migration
tools (Ibidi GmbH).
DiI-oxLDL/DiI-LDL uptake/foam cell formation. MIF/CXCR4-dependent foam
cell formation was assessed by measuring uptake of fluorescently labeled oxidized
or native human low-density lipoprotein particles (DiI-oxLDL or DiI-LDL,
respectively) in primary human monocyte-derived macrophages essentially fol-
lowing an established protocol41. Briefly, cells were incubated in culture medium
(RPMI 1640-GlutaMAx medium containing 100 U mL−1 penicillin, 100 μg mL−1
streptomycin, and 0.2% BSA) for 15 h at 37 °C and subsequently incubated in the
same medium supplemented with 1% HPCD ((2-hydroxy)-β-cyclodextrin, Sigma-
Aldrich) for 45 min. After washing with imaging solution (MEM without phenol
red containing 30 mM HEPES, 0.5 g/L NaHCO3, pH 7.4, and 0.2% BSA), cells were
exposed to 50 µg mL−1 1,1′-dioctadecyl-3,3,3′3′-tetramethylindocarbocyanine-
labeled oxidized LDL (DiI-oxLDL) or DiI-labeled native LDL (DiI-LDL) for 30 min
at 4 °C, followed by incubation at 37 °C for 20 min. Cells were washed with ice-cold
imaging solution (pH 3.5), fixed, and counter-stained with Hoechst 33258.
Static monocyte adhesion. HAoECs were seeded at a density of 30,000 cells/well
in 6 well µ-Ibidi Perfusion slides VI 0.4 (Ibidi GmbH). After confluency was
reached, TNF-α or MIF were added at a final concentration of 4 or 16 nM,
respectively, in the presence versus absence of msR4M-L1 (320 nM), and cells
incubated for 16 h. To mimic chronic atherogenic inflammatory conditions, cells
were pre-treated with 40 pM human TNF-α before adding MIF. After perfusion of
the chambers with fresh medium, MonoMac6 cells (1 × 106 cells mL−1) in Pro-
moCell medium were added for 30 min. Non-adhering cells were flushed away by
gentle perfusion using a 30 mL syringe. To quantify adherent monocytes, seven
individual images (technical triplicates each) from each treatment were acquired
using a Leica DMi8 inverted microscope with a ×10 objective and cells quantified
using ImageJ.
Monocyte adhesion under flow. HAoECs were seeded at a density of 60,000 cells
per channel in collagen-coated Ibidi µ-Slides I 0.8 and incubated for 20–24 h until
monolayers were confluent. HAoECs were treated with 16 nM human MIF in the
presence versus absence of msR4M-L1 (320 nM) for 2 h. MonoMac6 cells were
exposed to human MIF and msR4M-L1 at the same concentrations for 2 min,
before they were transferred into assay buffer (1 x HBSS, 10 mM HEPES, 0.5%
BSA) at a density of 0.5 × 106 cells mL−1 and kept at 37 °C. Prior to the flow assay,
MgSO4 and CaCl2 were added to MonoMac6 suspensions at a final concentration
of 1 mM. Flow channels containing HAoEC monolayers were then perfused with
MonoMac6 cells at a shear rate of 1.5 dyn cm−2 for 10 min at 37 °C using the Ibidi
Pump System/Perfusion Set. For quantification of adherent monocytes, images
from four positions per channel were acquired using a Leica DMi8 inverted
microscope (20 x objective) and quantified with ImageJ.
Staining of atherosclerotic plaque tissue with Fluos-msR4M-L1. Immuno-
fluorescent staining of atherosclerotic tissue with Fluos-msR4M-L1 was performed
with specimens from atherogenic Ldlr−/− and Apoe−/− mice. Ldlr−/− mice were
on chow diet for 30 weeks and developed native atherosclerotic lesions as reported
previously14. Mif-deficient mice (Ldlr−/− Mif−/−) were used for comparison.
Aortic root sections were deparaffinized and rehydrated. For antigen retrieval,
slides were boiled in sodium citrate buffer, pH 6.0, 0.05% Tween 20, and blocked
with PBS, containing 5% donkey serum and 1% BSA. For staining, slides were
incubated at 4 °C with Fluos-msR4M-L1 (5 µM) in blocking buffer. DAPI was used
for nuclear counterstain and sections were imaged using a Leica DMi8 fluorescent
microscope. The mean fluorescence intensity localized to the aortic vessel wall was
quantified via ImageJ, accounting for autofluorescence background signals.
For Apoe−/− mice (and Apoe−/−Mif−/− as control66), cryo-conserved sections
of advanced lesions from brachiocephalic artery (BC) were used from mice on
Western-type high-fat diet (HFD, 1.25% cholesterol) for 24 weeks. Slides were fixed
in ice-cold acetone, rehydrated in PBS, and blocked in PBS/1% BSA, incubated with
500 nM Fluos-msR4M-L1, and analyzed as above.
Fluos-msR4M-L1 staining and monocyte adhesion in atherosclerotic carotid
arteries by multiphoton microscopy. Monocyte adhesion experiments in ather-
osclerotic carotid arteries under physiological flow conditions ex vivo have been
established14,75 and were performed by a slight modification of this procedure.
Briefly, seven-week-old Apoe−/− mice were fed a Western-type HFD (0.2% cho-
lesterol) for 12 weeks. The last 3 days before sacrifice, mice were injected with
msR4M-L1 (100 μg, once daily) or sterile saline (control). On day 3, arteries were
prepared and mounted into an arteriograph chamber. Carotids were flushed with
buffer-containing msR4M-L1 (3 µM). Mouse leukocytes isolated from the bone
marrow of msR4M-L1- or vehicle-treated atherogenic Apoe−/− mice were stained
with fluorescent Green CMFDA or Red CMPTX (Thermo Fisher Scientific). After
washing with Hank’s Balanced Salt Solution (HBSS), stained leukocytes were
incubated with 3 µM msR4M-L1 (red) or PBS (green, control) for 1 h at 37 °C. The
red- and green-stained cell pools were mixed at a 1:1 ratio and 3 × 106 cells in 6 mL
perfused into the artery of msR4M-L1- or vehicle-treated mice, respectively.
Arteries were scanned by MPM using a multispectral TCS SP8 DIVE instrument
with filter-free 4TUNE NDD detection module (Leica) and the number of adherent
and transmigrated leukocytes determined by scanning multiphoton excitation.
Vessel structure (and plaques) were visualized by second harmonic generation
(SHG). Image acquisition, visualization, and processing was performed using the
LAS X SP8 software package with LAS X 3D visualization and analysis (Leica) and
LAS X HyVolution 2 packages from Leica/SVI Huygens, (Laapersveld, NL).
For plaque staining with Fluos-msR4M-L1 in atherosclerotic carotid arteries
and aortic roots, Fluos-msR4M-L1 was i.p.-injected into aged atherogenic Apoe−/−
mice (24-week HFD) three days before carotid preparation (50 µg per mouse, once
daily). Aortic roots were fresh-frozen and cut into 8 µm-sections and whole-mount
carotid arteries prepared for MPM as above. After recording Fluos-msR4M-L1
signals in aortic root sections by MPM, sections were stained by oil Red O (ORO)
solution (0.5% in propylene glycol). The Fluos-msR4M-L1-positive area was
quantified by ImageJ as a percentage of whole target area (ORO+ for aortic root,
plaque area for carotid).
Proteolytic stability assay. Mouse plasma was prepared from blood of wildtype
C57/BL6 mice by standard procedure. TAMRA-msR4M-L1 dissolved in 1 mM
HCl, mixed with PBS, and added to mouse plasma (final concentration 482 nM)
and mixtures incubated at 37 °C for various time intervals up to 48 h. Samples were
then diluted in 2x Novex Tricine SDS sample buffer (Life Technologies) at a ratio
of 1:6, electrophoresed in a 10–20% Tricine gel, and red fluorescent bands directly
imaged with an Odyssey® Fc imager. Human plasma was prepared from blood of
healthy volunteers by standard procedure. Biotin-6-Ahx-msR4M-L1 was dissolved
in PBS and mixed with PBS or human plasma (final concentration 13.7 µM) and
solutions incubated for 0.5, 1, 4, or 16 h at 37˚C. Samples were electrophoresed as
above, transferred to nitrocellulose, and Biotin-6-Ahx-msR4M-L1 revealed by
streptavidin-POD conjugate (Roche Diagnostics, Mannheim, Germany; 1:5000
dilution), using an Odyssey® Fc imager.
In vivo stability of msR4M-L1 (pharmacokinetics). TAMRA-msR4M-L1 was
dissolved in sterile physiological saline (0.9% sodium chloride). C57BL/6 J mice
were i.p.-injected with a single dose of TAMRA-msR4M-L1 (50 µg per mouse,
corresponding to 2.5 mg/kg; one mouse per time point). Mice were sacrificed at 0,
0.5, 1, 2, 4, 6, 8, 24, and 48 h and blood collected by cardiac puncture into EDTA-
coated tubes. Plasma was immediately separated by centrifugation at 3000 rpm for
10 min at 4 °C, and placed on ice protected from light. Plasma aliquots were diluted
(1:1) with SDS-PAGE sample buffer, boiled, analyzed in 10–20% Tricine SDS-
PAGE gels, and red fluorescent bands imaged by Odyssey® Fc imager. Full-size gels
are supplied in the Source Data file.
Cytokine array. Cytokine/chemokine profiling was performed from plasma sam-
ples of msR4M-L1- versus vehicle-treated Apoe−/− mice using mouse cytokine
array panel A (R&D Systems, ARY006) according to the manufacturer’s instruc-
tions. Plasma samples were diluted (1:10) in array buffer; incubated with antibody
detection cocktail for 1 h at RT, exposed to the blocked membranes (overnight, 4 °
C), membranes washed and incubated with streptavidin-HRP conjugate working
solution (30 min, RT). Membranes were developed with Chemi-Reagent Mix and
analyzed by Odyssey® Fc imager. The average signal (mean signal intensity) of
duplicate spots was quantified by ImageJ.
In vivo model of atherosclerosis. Therapeutic injections of msR4M-L1 and aorta
preparation. Seven-eight-week-old female Apoe−/− mice were randomly divided
into two groups of 11–12 mice each and both groups put on a Western-type HFD
(0.21% cholesterol) for 4.5 weeks. Mice develop early-to-intermediate athero-
sclerotic lesions in this model44. One group was i.p.-injected with 50 µg msR4M-L1
dissolved in saline every other day for 4.5 weeks; controls received saline. No
toxicity or side effects were noted. At the end of the experiment, mice were
sacrificed, blood collected by cardiac puncture and saved for blood cell and lipid
measurements and mice transcardially perfused with saline. Hearts, proximal
aortas and carotid arteries were prepared and fixed for plaque morphometry and
lesion analysis.
Quantification of plaques and vessel morphometry (ORO and H&E staining).
Cut heart tissues containing aortic root were embedded in Tissue Tek optimum
cutting temperature (OCT) substance (Sakura Finetek, Osaka, Japan) and frozen at
−80 °C. Eight-µm sections were prepared for ORO staining and plaque immune
cell analysis. The accumulation of macrophages in aortic root lesions was
determined by an anti-MAC-2 antibody (1:100 dilution) followed by Cy5-
conjugated secondary antibody. Nuclei were visualized with DAPI. The aortic arch
was cut, fixed in 4% paraformaldehyde (PFA) and embedded in paraffin. Four-µm
sections containing the three branches (brachiocephalic, left common carotid, and
left subclavian artery) were prepared and stained with hematoxylin/eosin (H&E)
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for vessel morphometry. Images were captured with a Leica DMi8 microscope and
quantified using ImageJ.
Blood cell counts, triglycerides and cholesterol levels. Blood was collected in
EDTA tubes and leukocytes and plasma obtained by centrifugation at 630 × g (10
min, 4 °C). For leukocyte counts, red blood cells (RBC) were depleted by RBC-lysis
buffer (BioLegend) at RT, leukocytes washed and suspended in PBS containing
0.5% BSA. Cells were stained with an antibody cocktail comprising APC-Cy-7-
conjugated anti-CD45, PE-conjugated anti-CD11b, APC-conjugated anti-CD19,
FITC-conjugated anti-CD3, APC-conjugated anti-Ly6C, and PE-conjugated anti-
Ly6G (BD Biosciences). Measurements were analyzed using a BD FACSVerse™ flow
cytometer and data quantified using FlowJo software. The gating strategy for the
blood leukocyte analysis is shown in Supplementary Fig. 24.
Total cholesterol and triglyceride concentrations were measured enzymatically
using routine cholesterol fluorometric and triglyceride colorimetric assay kits,
respectively (Cayman Chemical Company, Ann Arbor, USA).
Analysis of human carotid atherosclerotic plaques. Patient population, study
groups and tissue samples. Carotid artery tissue samples came from the Munich
Vascular Biobank (MVB) and were from patients who underwent carotid endar-
terectomy (CEA) in the Department of Vascular and Endovascular Surgery at
University Hospital of Technische Universität München. Healthy carotid vessels
were obtained from the Forensic Medicine Department. Sample processing for
histological analysis was performed by an established procedure46,76. Briefly, car-
otid specimens were fixed in formalin and embedded in paraffin (FFPE), cross-
sections of 2–3 µm were prepared and stained with H&E and Elastica-van-Gieson
(EVG) to evaluate tissue histomorphology and plaque vulnerability. Atherosclerotic
lesions were characterized according to the American Heart Association (AHA)
guidelines77. All FFPE stable or unstable carotid tissues showed advanced ather-
osclerosis (stage V–VII). Fresh tissue samples were processed immediately as
detailed below and were rendered stage I-III (early) or stage V-VII (advanced)
based on the aforementioned classification after Stary77. The study was approved
by the local ethical committee of the University Hospital (Committee 2799/10 and
5290/12; “Ethikkommission der Fakultät für Medizin der Technischen Universität
München, Munich, Germany) and followed the Guidelines of the World Medical
Association Declaration of Helsinki. All patients provided informed consent.
Quantitative polymerase chain reaction (qPCR). For qPCR from FFPE sections,
total mRNA was isolated from 19 stable and 20 unstable human CEA plaques, and
from 4 healthy vessel tissue sections, using High Pure RNA Paraffin kit (Roche)
following an established procedure46. The mRNA was reverse-transcribed using
First Strand cDNA synthesis kit (Thermo Scientific), and qPCR reactions run using
ORA™SEE qPCR Green ROX H MIX (HighQu, Germany).
Primers used were: MIF forward, 5′→3′ AGA ACC GCT CCT ACA GCA AGC;
MIF reverse, 5′→3′ GGA GTT GTT CCA GCC CAC AT; actin forward, 5′→3′
AGA GCT ACG AGC TGC CTG AC; actin reverse, 5′→3′ CGT GGA TGC CAC
AGG ACT.
For qPCR from fresh tissue samples, CEA tissue of nine early versus nine
advanced plaque stages (age- and gender-matched), was homogenized in QIAzol
lysis reagent (Qiagen, Netherlands) and total RNA isolated using the miRNeasy
Mini Kit (Qiagen) according to manufacturer´s instruction. First strand cDNA
synthesis was performed using the High-Capacity-RNA-to-cDNA Kit (Applied
Biosystems, USA).
Quantitative real-time TaqMan PCR was performed using commercial primers
from Thermo Fisher (MIF: Hs00236988_g1; RPLP0: HS00420895_gH). PCRs were
run on a QuantStudio5 Cycler (Applied Biosystems, USA). Gene expression was
normalized to Rplp0 and quantified with the 2^ΔΔCt method.
RNA sequencing (RNAseq). Library preparation was performed using the
TruSeq Stranded Total RNA Library Prep Kit with Ribo-Zero (Illumina, Berlin,
Germany). Briefly, human carotid artery tissue from was homogenized in QIAzol
lysis reagent (Qiagen, Netherlands), total RNA isolated using the miRNeasy Mini
Kit (Qiagen, Netherlands) according to manufacturer´s instruction, and RNA
integrity number (RIN) determined with the Agilent 2100 BioAnalyzer (RNA 6000
Nano Kit, Agilent). For library preparation 1 μg of RNA was depleted for
cytoplasmatic rRNAs, fragmented, and reverse transcribed. A-tailing, adaptor
ligation, and library enrichment were performed as described in the high
throughput protocol of the TruSeq RNA Sample Prep Guide (Illumina). RNA
libraries were assessed for quality and quantity with the Caliper LabChIP GX and
the Quant-iT PicoGreen dsDNA Assay Kit (Life Technologies). Libraries were
pooled and ran as 150 bp paired-end runs on an Illumina NovaSeq 6000 platform.
Immunohistochemistry/immunofluorescence staining. Immunofluorescence
staining of human CEA tissues (11 stable, 12 unstable plaques) and nine healthy
vessel controls with TAMRA-msR4M-L1 was performed using a similar protocol as
for paraffin-embedded specimens from Ldlr−/− mice (see above), except that 1.5
µM of the fluorescent probe was used. For the competition experiment with MIF
(54–80), 1.5 µM TAMRA-msR4M-L1 was pre-incubated with 3 µM MIF(54–80)
before adding the mixture to the CEA slides. TAMRA-msR4M-L1 staining was
corrected for autofluorescence, e.g. at tissue edges. Antibody-based detection of
MIF was performed applying the DAB+ kit (Abcam, ab64238) following a
standard protocol. MIF was detected with the polyclonal goat antibody N-20 (Santa
Cruz, sc-16965; 1:100) or protein A-purified IgG from rabbit anti-MIF polyclonal
serum Ka56514. HRP-conjugated polyclonal rabbit anti-goat immunoglobulin
(DAKO, P0160, 1:1000) or goat anti-rabbit immunoglobulin (Dako REAL™
Detection System, K5001) was used as secondary antibody. Slides were counter-
stained with Mayer's hematoxylin and stainings analyzed with a Leica DMi8.
Statistical analysis. Statistical analysis was performed using GraphPad Prism
version 6, 7, and 8 software. Data are represented as means ± SD. After testing for
normality using the D’Agostino-Pearson omnibus normality test, data were ana-
lyzed by two-tailed unpaired Student’s t test or by two-tailed Mann–Whitney U
test, or by one-way ANOVA with Tukey’s multiple comparisons test or
Kruskal–Wallis test with Dunn’s multiple comparisons test, as appropriate. Dif-
ferences with p < 0.05 were considered to be statistically significant.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The data supporting the findings of this study are available within the paper and its
Supplementary Information files. The crystal structures of human CXCR4 as used for
ectodomain peptide selection in this study are available as publicly available datasets
under the accession codes 3ODU, 3OE0, 3OE6, 3OE8, 3OE9, 4RWS. All other data are
available from the corresponding authors upon reasonable request. Source data are
provided with this paper.
Received: 2 December 2019; Accepted: 28 October 2020;
References
1. Charo, I. F. & Ransohoff, R. M. The many roles of chemokines and chemokine
receptors in inflammation. N. Engl. J. Med. 354, 610–621 (2006).
2. Bachelerie, F. et al. International Union of Basic and Clinical Pharmacology.
LXXXIX. Update on the extended family of chemokine receptors and
introducing a new nomenclature for atypical chemokine receptors. Pharm.
Rev. 66, 1–79 (2014).
3. Koenen, R. R. & Weber, C. Chemokines: established and novel targets in
atherosclerosis. EMBO Mol. Med. 3, 713–725 (2011).
4. Ridker, P. M. et al. Antiinflammatory therapy with Canakinumab for
atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017).
5. Proudfoot, A. E., Bonvin, P. & Power, C. A. Targeting chemokines: pathogens
can, why can’t we? Cytokine 74, 259–267 (2015).
6. Weber, C. & Noels, H. Atherosclerosis: current pathogenesis and therapeutic
options. Nat. Med. 17, 1410–1422 (2011).
7. Fernandez-Botran, R., Crespo, F. A. & Sun, X. Soluble cytokine receptors in
biological therapy. Expert Opin. Biol. Ther. 2, 585–605 (2002).
8. Calandra, T. & Roger, T. Macrophage migration inhibitory factor: a regulator
of innate immunity. Nat. Rev. Immunol. 3, 791–800 (2003).
9. Bernhagen, J. et al. MIF is a pituitary-derived cytokine that potentiates lethal
endotoxaemia. Nature 365, 756–759 (1993).
10. David, J. R. Delayed hypersensitivity in vitro: its mediation by cell-free
substances formed by lymphoid cell-antigen interaction. Proc. Natl Acad. Sci.
USA 56, 72–77 (1966).
11. Donnelly, S. C. et al. Regulatory role for macrophage migration inhibitory
factor in acute respiratory distress syndrome. Nat. Med. 3, 320–323 (1997).
12. Morand, E. F., Leech, M. & Bernhagen, J. MIF: a new cytokine link between
rheumatoid arthritis and atherosclerosis. Nat. Rev. Drug Discov. 5, 399–410
(2006).
13. Merk, M. et al. The D-dopachrome tautomerase (DDT) gene product is a
cytokine and functional homolog of macrophage migration inhibitory factor
(MIF). Proc. Natl Acad. Sci. USA 108, E577–E585 (2011).
14. Bernhagen, J. et al. MIF is a noncognate ligand of CXC chemokine
receptors in inflammatory and atherogenic cell recruitment. Nat. Med. 13,
587–596 (2007).
15. Miller, E. J. et al. Macrophage migration inhibitory factor stimulates AMP-
activated protein kinase in the ischaemic heart. Nature 451, 578–582 (2008).
16. Sinitski, D. et al. Macrophage migration inhibitory factor (MIF)-based
therapeutic concepts in atherosclerosis and inflammation. Thromb. Haemost.
119, 553–566 (2019).
17. Zernecke, A., Bernhagen, J. & Weber, C. Macrophage migration inhibitory
factor in cardiovascular disease. Circulation 117, 1594–1602 (2008).
18. Kleemann, R. et al. Intracellular action of the cytokine MIF to modulate AP-1
activity and the cell cycle through Jab1. Nature 408, 211–216 (2000).
19. Leng, L. et al. MIF signal transduction initiated by binding to CD74. J. Exp.
Med. 197, 1467–1476 (2003).
20. Qi, D. et al. The vestigial enzyme D-dopachrome tautomerase protects the
heart against ischemic injury. J. Clin. Invest. 124, 3540–3550 (2014).
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-19764-z
16 NATURE COMMUNICATIONS |         (2020) 11:5981 | https://doi.org/10.1038/s41467-020-19764-z | www.nature.com/naturecommunications
21. Assis, D. N. et al. The role of macrophage migration inhibitory factor in
autoimmune liver disease. Hepatology 59, 580–591 (2014).
22. Pantouris, G. et al. Nanosecond dynamics regulate the MIF-induced activity of
CD74. Angew. Chem. Int Ed. Engl. 57, 7116–7119 (2018).
23. Weber, C. et al. Structural determinants of MIF functions in CXCR2-mediated
inflammatory and atherogenic leukocyte recruitment. Proc. Natl Acad. Sci.
USA 105, 16278–16283 (2008).
24. Lacy, M. et al. Identification of an Arg-Leu-Arg tripeptide that contributes to
the binding interface between the cytokine MIF and the chemokine receptor
CXCR4. Sci. Rep. 8, 5171 (2018).
25. Rajasekaran, D. et al. Macrophage migration inhibitory factor-CXCR4
receptor interactions: evidence for partial allosteric agonism in comparison
with CXCL12 chemokine. J. Biol. Chem. 291, 15881–15895 (2016).
26. Doring, Y. et al. Vascular CXCR4 limits atherosclerosis by maintaining arterial
integrity: evidence from mouse and human studies. Circulation 136, 388–403
(2017).
27. Zernecke, A. et al. Delivery of microRNA-126 by apoptotic bodies induces
CXCL12-dependent vascular protection. Sci. Signal 2, ra81 (2009).
28. Spanopoulou, A. et al. Designed macrocyclic peptides as nanomolar amyloid
inhibitors based on minimal recognition elements. Angew. Chem. Int Ed. Engl.
57, 14503–14508 (2018).
29. Wu, B. et al. Structures of the CXCR4 chemokine GPCR with small-molecule
and cyclic peptide antagonists. Science 330, 1066–1071 (2010).
30. Qin, L. et al. Structural biology. Crystal structure of the chemokine receptor
CXCR4 in complex with a viral chemokine. Science 347, 1117–1122 (2015).
31. Crump, M. P. et al. Solution structure and basis for functional activity of
stromal cell-derived factor-1; dissociation of CXCR4 activation from binding
and inhibition of HIV-1. EMBO J. 16, 6996–7007 (1997).
32. Yan, L. M., Tatarek-Nossol, M., Velkova, A., Kazantzis, A. & Kapurniotu, A.
Design of a mimic of nonamyloidogenic and bioactive human islet amyloid
polypeptide (IAPP) as nanomolar affinity inhibitor of IAPP cytotoxic
fibrillogenesis. Proc. Natl Acad. Sci. USA 103, 2046–2051 (2006).
33. Eftink, M. R. Fluorescence methods for studying equilibrium macromolecule-
ligand interactions. Methods Enzymol. 278, 221–257 (1997).
34. Cisneros, J. A., Robertson, M. J., Valhondo, M. & Jorgensen, W. L. A
Fluorescence polarization assay for binding to macrophage migration
inhibitory factor and crystal structures for complexes of two potent inhibitors.
J. Am. Chem. Soc. 138, 8630–8638 (2016).
35. Klasen, C. et al. MIF promotes B cell chemotaxis through the receptors
CXCR4 and CD74 and ZAP-70 signaling. J. Immunol. 192, 5273–5284 (2014).
36. Bernhagen, J. et al. Purification, bioactivity, and secondary structure analysis
of mouse and human macrophage migration Inhibitory factor (MIF).
Biochemistry 33, 14144–14155 (1994).
37. Schober, A. et al. Stabilization of atherosclerotic plaques by blockade of
macrophage migration inhibitory factor after vascular injury in apolipoprotein
E-deficient mice. Circulation 109, 380–385 (2004).
38. Wong, H. S. et al. Chemokine signaling enhances CD36 responsiveness
toward oxidized low-density lipoproteins and accelerates foam cell formation.
Cell Rep. 14, 2859–2871 (2016).
39. Manning-Tobin, J. J. et al. Loss of SR-A and CD36 activity reduces
atherosclerotic lesion complexity without abrogating foam cell
formation in hyperlipidemic mice. Arterioscler Thromb. Vasc. Biol. 29, 19–26
(2009).
40. Patel, K. M. et al. Macrophage sortilin promotes LDL uptake, foam cell
formation, and atherosclerosis. Circ. Res 116, 789–796 (2015).
41. Domschke, G. et al. Systematic RNA-interference in primary human
monocyte-derived macrophages: A high-throughput platform to study foam
cell formation. Sci. Rep. 8, 10516 (2018).
42. Kerschbaumer, R. J. et al. Neutralization of macrophage migration inhibitory
factor (MIF) by fully human antibodies correlates with their specificity for the
β-sheet structure of MIF. J. Biol. Chem. 287, 7446–7455 (2012).
43. Leng, L. et al. A small-molecule macrophage migration inhibitory factor
antagonist protects against glomerulonephritis in lupus-prone NZB/NZW F1
and MRL/lpr mice. J. Immunol. 186, 527–538 (2011).
44. Rami, M. et al. Chronic intake of the selective serotonin reuptake inhibitor
fluoxetine enhances atherosclerosis. Arterioscler Thromb. Vasc. Biol. 38,
1007–1019 (2018).
45. Burger-Kentischer, A. et al. Expression of macrophage migration inhibitory
factor in different stages of human atherosclerosis. Circulation 105, 1561–1566
(2002).
46. Merckelbach, S. et al. Expression and Cellular Localization of CXCR4 and
CXCL12 in Human Carotid Atherosclerotic Plaques. Thromb. Haemost. 118,
195–206 (2018).
47. Rose-John, S. The soluble interleukin 6 receptor: advanced therapeutic options
in inflammation. Clin. Pharm. Ther. 102, 591–598 (2017).
48. Zlotnik, A., Burkhardt, A. M. & Homey, B. Homeostatic chemokine
receptors and organ-specific metastasis. Nat. Rev. Immunol. 11, 597–606
(2011).
49. Pawig, L., Klasen, C., Weber, C., Bernhagen, J. & Noels, H. Diversity and inter-
connections in the CXCR4 chemokine receptor/ligand family: molecular
perspectives. Front Immunol. 6, 429 (2015).
50. DiPersio, J. F., Uy, G. L., Yasothan, U. & Kirkpatrick, P. Plerixafor. Nat. Rev.
Drug Discov. 8, 105–106 (2009).
51. Schunkert, H. et al. Large-scale association analysis identifies 13 new
susceptibility loci for coronary artery disease. Nat. Genet. 43, 333–338 (2011).
52. Doring, Y. et al. CXCL12 derived from endothelial cells promotes atherosclerosis
to drive coronary artery disease. Circulation 139, 1338–1340 (2019).
53. Sjaarda, J. et al. Blood CSF1 and CXCL12 as causal mediators of coronary
artery disease. J. Am. Coll. Cardiol. 72, 300–310 (2018).
54. Liehn, E. A. et al. Double-edged role of the CXCL12/CXCR4 axis in
experimental myocardial infarction. J. Am. Coll. Cardiol. 58, 2415–2423
(2011).
55. Zernecke, A. et al. SDF-1alpha/CXCR4 axis is instrumental in neointimal
hyperplasia and recruitment of smooth muscle progenitor cells. Circ. Res. 96,
784–791 (2005).
56. Hu, X. et al. Stromal cell derived factor-1 alpha confers protection against
myocardial ischemia/reperfusion injury: role of the cardiac stromal cell
derived factor-1 alpha CXCR4 axis. Circulation 116, 654–663 (2007).
57. Saxena, A. et al. Stromal cell-derived factor-1alpha is cardioprotective after
myocardial infarction. Circulation 117, 2224–2231 (2008).
58. Zernecke, A. et al. Protective role of CXC receptor 4/CXC ligand 12 unveils
the importance of neutrophils in atherosclerosis. Circ. Res. 102, 209–217
(2008).
59. Fingerle-Rowson, G. et al. A tautomerase-null macrophage migration-
inhibitory factor (MIF) gene knock-in mouse model reveals that protein
interactions and not enzymatic activity mediate MIF-dependent growth
regulation. Mol. Cell Biol. 29, 1922–1932 (2009).
60. Barter, E. F. & Stone, M. J. Synergistic interactions between chemokine
receptor elements in recognition of interleukin-8 by soluble receptor mimics.
Biochemistry 51, 1322–1331 (2012).
61. Mobius, K., Durr, R., Haussner, C., Dietrich, U. & Eichler, J. A functionally
selective synthetic mimic of the HIV-1 co-receptor CXCR4. Chemistry 18,
8292–8295 (2012).
62. Pritz, S. et al. Synthesis of protein mimics with nonlinear backbone topology
by a combined recombinant, enzymatic, and chemical synthesis strategy.
Angew. Chem. Int Ed. Engl. 47, 3642–3645 (2008).
63. Mahalingam, D. et al. Safety and efficacy analysis of imalumab, an anti-
oxidized macrophage migration inhibitory factor (oxMIF) antibody, alone or
in combination with 5-fluorouracil/leucovorin (5-FU/LV) or panitumumab, in
patients with metastatic colorectal cancer (mCRC). Ann. Oncol. 2016, p. ii105
(2016).
64. Ziarek, J. J. et al. Structural basis for chemokine recognition by a G protein-
coupled receptor and implications for receptor activation. Sci. Signal 10,
eaah5756 (2017).
65. Chen, D. et al. Expression of human tissue factor pathway inhibitor on
vascular smooth muscle cells inhibits secretion of macrophage migration
inhibitory factor and attenuates atherosclerosis in ApoE−/− mice. Circulation
131, 1350–1360 (2015).
66. Schmitz, C. et al. Mif-deficiency favors an atheroprotective autoantibody
phenotype in atherosclerosis. FASEB J. 32, 4428–4443 (2018).
67. von Hundelshausen, P. et al. Chemokine interactome mapping enables
tailored intervention in acute and chronic inflammation. Sci. Transl. Med 9,
eaah6650 (2017).
68. Kang, I. & Bucala, R. The immunobiology of MIF: function, genetics and
prospects for precision medicine. Nat. Rev. Rheumatol. 15, 427–437 (2019).
69. Dessein, A. F. et al. Autocrine induction of invasive and metastatic phenotypes
by the MIF-CXCR4 axis in drug-resistant human colon cancer cells. Cancer
Res. 70, 4644–4654 (2010).
70. Lutgens, E. et al. Immunotherapy for cardiovascular disease. Eur. Heart J. 40,
3937–3946 (2019).
71. Henninot, A., Collins, J. C. & Nuss, J. M. The current state of peptide drug
discovery: back to the future? J. Med. Chem. 61, 1382–1414 (2018).
72. Andreetto, E. et al. A hot-segment-based approach for the design of cross-
amyloid interaction surface mimics as inhibitors of amyloid self-assembly.
Angew. Chem. Int Ed. 54, 13095–13100 (2015).
73. Asare, Y. et al. Inhibition of atherogenesis by the COP9 signalosome subunit 5
in vivo. Proc. Natl Acad. Sci. USA 114, E2766–E2775 (2017).
74. Yoo, S. A. et al. MIF allele-dependent regulation of the MIF coreceptor CD44
and role in rheumatoid arthritis. Proc. Natl Acad. Sci. USA 113, E7917–E7926
(2016).
75. van der Vorst, E. P. C. et al. Functional ex-vivo imaging of arterial cellular
recruitment and lipid extravasation. Bio-prot. 7, 2344 (2017).
76. Pelisek, J. et al. Biobanking: objectives, requirements, and future challenges-
experiences from the Munich Vascular Biobank. J. Clin. Med. 8, 251 (2019).
77. Stary, H. C. Natural history and histological classification of atherosclerotic
lesions: an update. Arterioscler Thromb. Vasc. Biol. 20, 1177–1178 (2000).
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-19764-z ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:5981 | https://doi.org/10.1038/s41467-020-19764-z | www.nature.com/naturecommunications 17
78. Megens, R. T. et al. Two-photon microscopy of vital murine elastic and
muscular arteries. Combined structural and functional imaging with
subcellular resolution. J. Vasc. Res. 44, 87–98 (2007).
Acknowledgements
This work was supported by Deutsche Forschungsgemeinschaft (DFG) grant SFB1123-
A3 to J.B. and A.K., DFG INST 409/209-1 FUGG to J.B., SFB1123-A1 to C.W., SFB1123-
Z2 to R.T.A.M., SFB1123-B3 to M.D. and Y.A., SFB1123-B5 to L.M. and by DFG under
Germany’s Excellence Strategy within the framework of the Munich Cluster for Systems
Neurology (EXC 2145 SyNergy—ID 390857198) to J.B., C.W., and M.D. C.W. is Van de
Laar Professor of Atherosclerosis and R.B. is Waldemar Von Zedtwitz Professor of
Medicine and supported by NIH R01 AR049610. A.H. is supported by a Metiphys
scholarship of LMU Munich. We thank Dr. Philipp von Hundelshausen and Dr. Xavier
Blanchet for providing recombinant CXCL12, Dr. Robert Kleemann for plaque speci-
mens from Ldlr−/− and Ldlr−/− Mif−/− mice, Mathias Holzner for assistance with the
chemotaxis experiments, Carolus Therapeutics, Inc. for providing MIF peptide frag-
ments, Dr. Thomas Hennes for cloning MIF(10xAla), and Simon Besson-Girard for help
with the statistical analyses. We thank Dr. Sophie Brameyer and the Biophysics Core
Facility at the School of Biology of LMU Munich and Prof. Michaela Smolle at the LMU
Biomedical Center for usage of their MST instruments. We thank the mass spectrometry
facilities of Technische Universität München (TUM) (Department of Chemistry,
Garching; Bavarian Center for Biomolecular Mass Spectrometry, BayBioMS, Freising) for
mass spectrometric measurements, Dr. Joana Viola-Söhnlein for help with the Luminex
instrument, and Dr. Dorothee Atzler for advice regarding the pharmacokinetic
experiments.
Author contributions
J.B. and A.K. conceived the project, and they designed experiments with contributions
from C.Ko., O.E., Y.A., R.T.A.M., L.L., R.B., O.G., and C.W. C.Ko., O.E., C.Kr., D.S., K.H.,
G.Y., C.Z., M.B., P.B., R.T.A.M., A.H., Y.G., Je.P., W.E.K., S.G., and S.W. conducted the
experiments. C.Ko., O.E., C.Kr., G.Y., C.Z., M.B., P.B., A.H., W.E.K., Y.G., and S.W.
contributed to data analysis. R.B., L.L., L.M., M.D., H.-H.E., W.E.K., and Ja.P. contributed
critical materials. J.B. and A.K. wrote the manuscript with contributions from all authors.
Funding
Open Access funding enabled and organized by Projekt DEAL.
Competing interests
J.B., R.B., and C.W. are co-inventors of patents covering anti-MIF strategies (antibodies,
small molecules, and MIF sequence-derived peptides) for inflammatory and cardiovas-
cular diseases. C.Ko., A.K., O.E., and J.B. are co-inventors of a patent application cov-
ering MIF-binding CXCR4 ectodomain mimics for inflammatory and cardiovascular
diseases. The remaining authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41467-
020-19764-z.
Correspondence and requests for materials should be addressed to A.K. or J.B.
Peer review information Nature Communications thanks Brian Volkman and the other,
anonymous, reviewer(s) for their contribution to the peer review of this work. Peer
reviewer reports are available.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2020
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-19764-z
18 NATURE COMMUNICATIONS |         (2020) 11:5981 | https://doi.org/10.1038/s41467-020-19764-z | www.nature.com/naturecommunications
